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Iterative chemical screening has resulted in optimized culture conditions to support 
the self-renewal of human and non-human primate pluripotent stem cells (PSCs) in a 
mouse embryonic stem cell-like ground state of pluripotency. While all protocols 
employ leukemia inhibitory factor (LIF) supplemented with MEK/ERK and GSK3-β 
inhibitors (LIF 2i), many indispensably require additional anti-apoptotic small 
molecules and primed growth factors. The finding of a minimal cocktail of LIF 2i 
plus axin-stabilizing XAV939 (termed LIF 3i) that efficiently reverts select myeloid 
progenitor hiPSC lines to a ground state advances the possibility that among 
heterogeneous PSCs, many lines are epigenetically more amenable to naïve reversion 
than others. Here, I report characterization of LIF 3i-permissive human naïve PSCs by 
examining transcriptome microarray data and OCT3/4 enhancer DNA methylation 
profiles. Additionally, I report an optimized feeder-dependent culture system to 
support naïve-like self-renewal in non-permissive rhesus macaque embryonic stem 
cells (rESCs) derived from in vitro fertilization (IVF), somatic cell nuclear transfer 
(SCNT), and parthenogenesis. Use of a potent VEGF receptor inhibitor, sunitinib 
malate, together with LIF 3i or LIF 2i, promoted naïve-like ground state self-renewal 
in rESCs. Efficient derivation and careful interrogation of human and non-human 
primate naïve PSCs before in vitro differentiation, plasmid-based gene targeting, or 
blastocyst complementation experiments is a necessary process to advance naïve 
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INTRODUCTION 
 
On primed and naïve pluripotent stem cells in mice and non-rodents 
 
A long-standing question in stem cell biology concerns the striking differences 
between primate and mouse pluripotent stem cells. Whether derived as embryonic 
stem cells (ESCs) from the inner cell mass (ICM) of blastocysts or as induced 
pluripotent stem cells (iPSCs) reprogrammed from differentiated somatic cells, mouse 
and human/non-human primate pluripotent stem cells (PSCs) exhibit pronounced 
phenotypic and epigenetic differences1. Cells from both species differ in their ability 
to integrate into the ICM of a mouse blastocyst, depend on different cytokine 
signaling requirements for undifferentiated self-renewal, appear morphologically 
distinct, and differ in their ease of single-cell cloning2. Specifically, mouse ESCs 
cultured in vitro with leukemia inhibitory factor (LIF) and small molecule inhibition 
of MEK/ERK and GSK3𝛽 (a culture cocktail termed “LIF 2i”), are preserved in a 
naive ICM-like state3,4. Removal of LIF 2i or culture with activin/FGF promotes 
naïve mouse cells to drift into a primed pluripotent state resembling the post-
implantation epiblast5. Until recently, all human pluripotent stem cell lines have 
existed in the primed variety. A comparison of phenotypic, molecular, and epigenetic 
features reveals why: naïve ICM-like mouse cells display dome-shaped morphology, 
utilize the distal enhancer for driving OCT4 (POU5F1) expression, exhibit global 
DNA demethylation, retain a pre-inactivation X chromosome state, and display 
H3K27me3 repressive chromatin marks on regulatory gene promoters important for 
development6. On the other hand, the novel discovery of primed mouse epiblast stem 
cells (EpiSCs)5,7 has revealed that EpiSCs are remarkably similar to conventional 
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FGF-dependent human pluripotent stem cells. These properties include flat colony 
morphology, predominant utilization of the proximal enhancer to drive OCT4 
expression, X chromosome inactivation, increased global DNA methylation, and 
acquisition of H3K27me3/bivalent domain marks on genes important for lineage 
commitment8,9. Table 1 summarizes the fundamental differences between the primed 









In vitro culture 
terminology 
Rodent EpiSCs; primate 
“primed” ESCs 
Rodent ESCs; and primate 
“naïve” ESCs 
In vivo embryonic tissue 
correlate 
Egg cylinder or embryonic 
disc 
ICM or early epiblast 
Ability to form blastocyst 
chimeras 
No Yes 
Ability to form teratomas Yes Yes 
Pluripotency factors OCT4, SOX2, NANOG OCT4, NANOG, SOX2, 
KLF2, KLF4 
Naïve Markers Absent STELLA (DPPA3), 
NR5A2, REX1, NROB1, 
FGF4 
Markers of specification FGF5, T Absent 
Differentiation bias Line-dependent and 
variable 
None 
Effect of LIF/STAT3 
signaling 
None Self-renewal 
BMP4 responsive No Yes 
Effect of FGF/ERK Self-renewal Differentiation 
Effect of 2i 
supplementation 
Death and differentiation Self-renewal 
Single cell clonogenicity Weak Strong 
Doubling times 24-26 hours 12-14 hours 
Morphology Flat Dome-shaped 
OCT4 enhancer 
predominance 
Proximal enhancer (PE) Distal enhancer (DE) 
XX status XaXa XaXi 
	  
Table 1: A literature-based synthesis of naïve versus primed pluripotent states 
Modified from Nichols and Smith (2009)1. Abbreviations: XaXa = both active X 
chromosomes; while XaXi = one active and one inactive X chromosome. 
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A comparison of naïve versus primed pluripotent stem cells has led many to speculate 
whether a naïve mouse-like state in human stem cells could be preserved in vitro. It is 
estimated that mice and humans diverged approximately 92.3 million years ago10 and 
primarily, the challenge of deriving mouse-ESC-like cells in humans has been 
attributed to the peri-implantation requirement for LIF/STAT signaling during 
diapause, a developmental stage nonexistent in humans11. Certainly, derivation of 
human ground state naïve pluripotent stem cells would offer tremendous benefits for 
regenerative medicine. Ease of single cell cloning, rapid doubling times, likely 
improved in vitro differentiation, ability to integrate into the ICM/ability to form 
chimeras, and amenability for plasmid-based gene targeting via homologous 
recombination (HR) are some of the novel benefits promised by generating naïve 
human pluripotent stem cells. Figure 1 examines the key differences between ground 
state pluripotency in mice and humans and depicts the various culture conditions 
required for deriving primed pluripotent stem cells and naïve pluripotent stem cells. 
 
At the molecular level, what transcription factor programs mediate the phenotypic 
differences seen between naïve and primed pluripotent states? How can we visualize 
the potency of naïve pluripotency compared to primed pluripotency? Figure 2 details 
the changing epigenetic landscape and transcription factor circuitry seen across the 
transition from naïve pluripotency to lineage segregation. Five key stages of stem cell 
potency are described: naive pluripotency, a reversibility phase, a transitional state, 
primed pluripotency, and lineage segregation. We must appreciate that sustaining 
naïve human pluripotency is akin to capturing a transient stage seen during embryonic 
development and attempting to preserve that stage in vitro indefinitely. As depicted in 
Figure 2A, the natural progression for naïve cells is to lose potency over time (i.e. 
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lose “potential energy”). Figure 2B shows that the exit from the ground state is 
reversible until cells reach a transitional state after which naïve ES cell identify is 
permanently lost12. The naïve ground state represents a globally demethylated state 
with unique chromatin and DNA repair properties. Having globally open chromatin 
means that the naïve cell represents a powerful tool to extinguish differentiation bias 
and improve differentiation potential (notice how much “higher” along Waddington’s 
Epigenetic Landscape the ground state stands compared to the primed state; Figure 
2A). When coupled together with a potentially activated HR double-stand break DNA 
repair system, the naïve cell represents a platform for efficient plasmid-based gene 
targeting via HR. 
 
What attempts have been made recently to derive ground state stem cells? Fortunately 
for regenerative medicine, pragmatic genetic and chemical manipulation has allowed 
several groups to convert mouse EpiSCs into ground state cells13–15. In this regard, 
Hanna et al. have employed 2i medium (either CHIR/PD or CHIR/Kenpaullone) 
supplemented with exogenous transgene-based KLF4 or c-MYC13. Note that 
Kenpaullone (KP) is a potent inhibitor of GSK3𝛽 and CDK1/cyclin B16–18 and the 
basis for choosing KP to revert mouse EpiSCs to ICM-like mESCs relies on the fact 
that KP is able to replace ectopic KLF4 during the reprogramming of somatic cells to 
iPSCs19. Similarly, Guo et al. employ KLF4 overexpression with 2i conditions14, 
while Silva et al. demonstrate that NANOG overexpression amidst 2i conditions is a 
critical determinant for conversion of EpiSCs into mESCs15. While NANOG is 
initially dispensable during transcription factor iPSC reprogramming to ground state 
iPSCs, Silva et al. demonstrate that dedifferentiated intermediates require NANOG 
expression to completely transition towards ground state self renewal15. Therefore, 
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transcriptional NANOG functions as the “gateway” to the ground state of 
pluripotency.  Transgene-based conversion has also been achieved for human primed 
cells9,20. Hanna et al. demonstrate the rewiring of primed hESCs towards a naïve-like 
mESC state with ectopic induction of Oct4, Klf4, and Klf2 factors amidst LIF 2i 
medium9, and Wang et al. describe the powerful finding that overexpression of the 
four Yamanaka factors (OCT4, SOX2, KLF4, c-MYC) together with retinoic acid 
receptor gamma (RAR-𝛾) and liver receptor homolog 1 (LRH-1 or NR5A2) during 
the reprogramming of primary human neonatal and adult fibroblasts is able to induce 
mESC-like self renewal20. These ground state iPSC display growth properties, gene 
expression signatures, and signal dependencies that align with canonical ICM-like 
mESCs20.  
 
Of interest, however, are the recent reports of transgene-free conversions of primed 
pluripotent human and rhesus macaque PSCs into putative naïve mouse-like cells21–27. 
Of these recent reports, the majority of groups employ various small molecule 
inhibitors and recombinant growth factors to block differentiation and stimulate 
LIF/STAT self-renewal (notably, JAK/STAT3 activation is sufficient to enable 
induction of a naïve pluripotent state even amidst antagonistic cues28). However, 
Ware et al. are the only group of the recent protocols to omit exogenous human LIF24. 
To summarize the recent transgene free naïve protocols, Table 2 depicts individual 
culture conditions used by the various groups. The work of Zimmerlin et al. (2015), 
which is currently under review, is also included for comparison purposes. Note that 
of all previous transgene-free naïve conversion formulas, only the LIF 3i cocktail of 
Zimmerlin et al. closely parallels classical LIF 2i conditions (most groups succumb to 
the use of multiple complex anti-apoptotic small molecule inhibitors and primed 
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growth factors.) While it may seem that the cocktail of Takashima et al.26 also closely 
parallels classical LIF 2i (they employ LIF 2i with the protein kinase C inhibitor 
Gö6983 that acts to suppress mouse ES cell differentiation29), the Jacob Hanna lab 
has found that this LIF 2i + Gö6983 combination is insufficient to produce genetically 
unmodified naïve human pluripotent stem cells in their hands30. One reason for this 
may be the genetically modified pluripotent stem cells used by Takashima et al., 
which use doxycycline (DOX) to drive NANOG-KLF2 expression. The NANOG and 
KLF2 transgenes may be leaky even in the absence of DOX and this effectively 
renders the transgene-free cocktail of Takashima et al. as LIF 2i/Gö6983 + leaky 
NANOG-KLF2 expression (which is obligatory to maintain select clones that can 
tolerate the somewhat harsh LIF 2i/ Gö6983 conditions).  
 
Additionally, the cocktail of Chan et al.22 also may seem to parallel classical LIF 2i 
conditions. While they omit primed growth factors like Zimmerlin et al., they employ 
the bone morphogenetic protein (BMP) signaling inhibitor Dorsomorphin. The use of 
Dorsomorphin here defies conventional literature describing BMP4 responsiveness in 
classically naïve mESCs. Ying et al. demonstrate that serum withdrawal promotes 
neural precursor differentiation of mESCs31; however, remarkably, exogenous BMP4 
supplementation can replace serum in mESC culture (when combined with exogenous 
LIF) to promote ground state self renewal32. The implication here is that BMP 
synergistically cooperates with LIF to sustain ground state self renewal of mESCs, 
and while the effect of BMP alone is to promote non-neural differentiation33,34, 
BMP/LIF together blocks ES cell differentiation. Mechanistically, BMP suppresses 
the differentiation of ES cells primarily via induction of Id genes, which are classical 
basic helix-loop-helix transcription factor antagonists32,35,36. Given such information, 
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the use of the BMP inhibitor Dorsomorphin by Chan et al. in their human naïve 
formulation defies classical definitions for ground state self-renewal set forth by 
Austin Smith and colleagues3. It is especially intriguing that Chan et al. find that BMP 
inhibition supports naïve human pluripotency considering that they also employ 
exogenous human LIF. It is for this reason that the BMP4-responsive formulation of 
Zimmerlin et al. stands above the other leading protocols as the most authentic 
formulation to support mESC-like naïve human pluripotency (BMP4-responsivenss 
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bFGF  bFGF bFGF   bFGF  





MEKi MEKi MEKi MEKi MEKi MEKi MEKi MEKi 
GSK3𝛽i GSK3𝛽i GSK3𝛽i GSK3𝛽i GSK3𝛽i GSK3𝛽i GSK3𝛽i GSK3𝛽i 
       XAV939 
ROCKi  ROCKi  ROCKi    
JNKi      JNKi  
P38i      P38i  
PKCi     PKCi   
 BMPi       
    BRAFi    
    SRCi    
	  
Table 2: A literature-based synthesis of current transgene-free non-rodent naïve 
culture conditions 
Note that the protocol for naive conversion using the formula of Ware et al. (2014) 
involves preculture with the histone deacetylase (HDAC) inhibitors butyrate and 
suberoylanilide hydroxamic acid. Abbreviations: KOSR = knockout serum 
replacement; MEF = mouse embryonic fibroblasts; hLIF = human leukemia inhibitory 
factor; TGF𝛽 = transforming growth factor beta; bFGF = basic fibroblast growth 
factor; MEK = mitogen-activated protein kinase kinase; GSK3𝛽 = glycogen synthase 
kinase 3 beta; ROCK = rho-associated protein kinase; JNK = c-Jun N-terminal protein 
kinase; PKC = protein kinase C; BMP = bone morphogenetic protein; BRAF = proto-
oncogene B-Raf; and SRC = proto-oncogene tyrosine-protein kinase Src. 
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Human stem cells with stable and authentic mouse ESC-like properties 
 
As depicted in Table 2, our group recently formulated a novel minimal naïve cocktail 
to convert primed human pluripotent cell lines into a mouse-like state (unpublished 
data, 2015). Authored by Zimmerlin, Park, and Huo et al., the work is currently under 
review. The cocktail consists of XAV939 (which stabilizes axin) above the classical 
LIF 2i formulation developed by Austin Smith and colleagues3 (which consists of 
exogenous LIF supplemented with MEK/ERK inhibition via the action of PD0325901 
and GSK3𝛽 inhibition via the action of CHIR99021). Of interest is the novel WNT 
modulation mediated by XAV939. As a chemotherapeutic agent, XAV939 globally 
inhibits WNT signalling37 by stabilizing the 𝛽-catenin destruction complex; however 
the combination of CHIR99021 with XAV939 acts to increase cytoplasmic-nuclear 
shuttling of active 𝛽-catenin38. In similar vein, the small molecule IWR-139 (also an 
axin stabilizer) in combination with CHIR99021 also seems to promote human ESC 
self renewal38. It is interesting to note that the non-transcriptional accumulation of 
active 𝛽-catenin in the cytoplasm (together with augmented active nuclear 𝛽-catenin) 
is suggested to stabilize the naïve state via interactions with cytoplasmic NANOG and 
OCT4, and surface E-cadherin40,41. Zimmerlin et al. argue that a prerequisite for 
efficient reversion to a stable human ground state is more effective reprogramming 
and reduced human PSC lineage priming. They demonstrate that their optimized 
stromal-priming method of converting human myeloid progenitors into human iPSCs 
produces pluripotent donors with de novo activated 𝛽-catenin in the cytoplasm and 
essentially “readies” their high-fidelity pluripotent donors for efficient minimal-
cocktail conversion to a ground state.  
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The LIF 3i cocktail of Zimmerlin et al. converts a variety of cord-blood derived 
human iPSC, human fibroblast iPSC, and human ESC lines into classical ground-state 
pluripotent stem cells with high efficiency (unpublished data, 2015). The culture 
conditions promote dome-shaped morphology, global DNA demethylation and 
reactivation of the X chromosome. Complex bioinformatics analyses of microarray 
data reveals that LIF 3i naïve human pluripotent cells share a global transcriptional 
signature that clusters with conventional ground state mouse ESCs (unpublished data, 
2015). Furthermore, current attempts to differentiate stable LIF 3i ground state cells 
demonstrate that conversion to a naive state may result in improved multi-lineage 
directed differentiation potency, quality, and kinetics. 
 
The impact of deriving authentic ground state human and rhesus PSCs 
 
As Figure 2A illustrates, the naïve ground state represents a favorable high point for 
stem cell potency in vitro. As regenerative medicine advances, more emphasis will be 
placed onto diversified cellular platforms that provide many avenues for gene 
correction and regenerative therapy. The generation of authentic ground state non-
rodent cells speaks to this imminent need and the following three areas of gene 
targeting, in vitro differentiation, and in vivo organ generation are discussed below as 
high-impact applications of non-rodent naïve PSCs.  
 
A paradigm shifting methodology for stem cell biology and regenerative medicine 
	  
The derivation of stable ground state human stem cells pioneers new avenues for in 
vitro gene repair and directed differentiation to operate with clinically relevant 
efficiencies and kinetics. Figure 3A describes the clinical iPS cell paradigm pre-naïve 
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technology. Here, patient-specific iPS cells have the potential to be used for in vitro 
differentiation and drug screening/modeling; while combining gene editing of iPS 
cells together with directed in vitro differentiation creates an opportunity for patients 
suffering from degenerative disorders to receive gene-corrected genetically matched 
cell-based transplantations. Post-naïve technology, we see that this paradigm can be 
revised (Figure 3B). Given that naïve stem cells have (1) the potential to undergo 
more efficient gene targeting via plasmid-based homologous recombination; and (2) 
possess little to no differentiation lineage-bias (Figure 2A and 2B), incorporating a 
naïve reversion step into the current iPS cell paradigm may allow genome editing and 
directed differentiation to operate with clinically relevant quality, potency, and 
kinetics. Presumably, the globally open chromatin landscape of naïve cells allows 
homologous recombination machinery favorable access to DNA (to allow potentially 
more efficient gene targeting over their primed counterparts) and similarly, the global 
“high point” of the naïve stem cell may extinguish any line-dependent lineage-bias 
during directed differentiation.  
 
Towards improving gene targeting via plasmid-based homologous recombination 
	  
While yet to be definitively shown, reversion to an authentic naïve state likely confers 
increased amenability for gene editing via plasmid-based homologous recombination 
(HR). Since the revolution of gene targeting in mouse ESCs pioneered by Mario R. 
Capecchi, Martin J. Evans, and Oliver Smithies, the belief was that gene targeting 
using electroporated linearized plasmid constructs (Figure 4A) would transition 
seamlessly into human pluripotent cells for mechanistic studies, disease-specific 
modeling, and transplantation therapy. However, conventional primed plasmid-based 
gene targeting frequencies in human pluripotent cells have been low42–46. The belief 
	   12	  
for the low efficiency of HR is two-fold: (1) primed cells have a tighter global 
chromatin structure (due to increased DNA methylation) and therefore HR machinery 
cannot access requisite DNA sequences with ease and (2) primed cells exhibit 
reduced capacity for gene targeting due to a more active non-homologous end joining 
(NHEJ) pathway47 (the competing pathway in double-strand break DNA repair). 
While helper-dependent adenoviral vectors (HDAdVs) with large 36 kb cloning 
capacities48 have the ability to deliver large targeting constructs into pluripotent stem 
cells and overcome limitations of weak HR in primed cells, the construction of 
HDAdVs is labor-intensive and technically challenging, and often HDAdVs may 
permanently integrate into the genome to pose an oncogenic threat49 (Figure 4A). In 
order to solve the weak HR capability of primed PSCs, researchers have turned to 
using synthetic nucleases to create sequence-specific double-strand breaks in human 
primed PSCs. In the presence of a single-stranded or double-stranded donor sequence, 
primed cells will more efficiently carry out HR at a synthetic break site (compared to 
no DSB). Zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases 
(TALENs), and the leading RNA-guided candidate, clustered regularly interspaced 
short palindromic repeat-associated nuclease 9 (CRISPR-Cas9) technology are three 
nuclease-assisted methods currently employed in genome editing applications (Figure 
4A). ZFNs and TALENs, which are prone to induce off target effects, are modular 
proteins with DNA binding domains and FokI nuclease activities49, while the more 
specific RNA-guided Cas9 nuclease offers greater genome editing precision and 
efficiency. 
 
When plasmid-based homologous recombination is employed in primed cells, 
electroporated constructs follow one of two fates: either targeted integration via HR, 
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or random integration via NHEJ (Figure 4B). Synthetic nuclease-induced repair 
either follows homology-directed repair (HR), to create sequence-specific edits, or 
error prone NHEJ, which often induces mutational insertions and deletions or indels 
(Figure 4C). Given the complexity associated with working with ZFNs, TALENs, or 
CRISPR-Cas9 technologies, and the fact that these technologies are prone to off target 
effects, classical plasmid-based HR still represents an effective way to precisely edit 
the genome. Here, the naïve pluripotent advantage paves the way for re-introduction 
of plasmid-based HR into human PSC genome editing. While primed PSCs possess 
tighter chromatin and endogenous enzymatic machinery biased towards NHEJ 
(Figure 4D), naïve PSCs likely possess looser chromatin and endogenous DSB DNA 
repair machinery biased towards HR (Figure 4E). It is for this reason that naïve PSCs 
represent a promising target for gene correction. 
 
The role of XAV939 in naïve pluripotency and non-homologous end joining 
	  
Does the naïve background offer further benefits for gene targeting via homologous 
recombination? Examination of the LIF 3i culture conditions for naïve reversion from 
Zimmerlin et al. reveals that the singular use of XAV939 may offer potential benefits 
for HR in the naïve background. While primarily used to mediate axin-stabilization 
and subsequent accumulation of non-transcriptional activated 𝛽 -catenin in the 
cytoplasm (which is important for reversion to a stable mouse ESC-like naïve state), 
XAV939 inhibits poly-ADP-ribosylating enzymes tankyrase 1 (TNKS1) and 
tankyrase 2 (TNKS2)37. As bona fide poly(ADP-ribose) polymerases (PARPs)50,51, 
TNKS1 and TNKS2 have diverse cellular roles. Of interest to gene targeting, 
however, is the relationship between TNKS1 and DNA-dependent protein kinase 
(DNA-PK) catalytic subunit (DNA-PKCS). Under normoxic conditions, Figure 5A 
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illustrates that in connection with NHEJ, DNA-PKCS is recruited to a DNA DSB site. 
At the same DSB site, HR competes with NHEJ to repair the break (HR is 
preferentially active during S and G2 phases of the cell cycle, while error prone NHEJ 
can be used within any phase of the cell cycle). Within 1-6 hours after recognition of 
DNA damage, HR and NHEJ proteins are recruited to repair the DSB52. Within the 
NHEJ pathway alone, DNA-PKCS plays a critical role in the initial phases of 
repairing a DSB and acts to recruit key ligases and processing enzymes to the damage 
site53 (Figure 5B).  
 
Given that HR and NHEJ are in competition to repair a DSB (particularly in S and G2 
phases of the cell cycle), it is apparent that suppression of NHEJ would preferentially 
favor HR-based repair and lead to improved targeted integration frequencies for gene 
targeting vectors. Here, use of XAV939 in the naïve cocktail of Zimmerlin et al. may 
play a powerful role. As a potent inhibitor of TNKS1, XAV939 acts to indirectly 
inhibit NHEJ54 via depletion of DNA-PKCS, and therefore, may improve gene 
targeting efficiencies in human PSCs converted with LIF 3i (compared to other naive 
conversion cocktails which do not employ XAV939). Interestingly, XAV939-
mediated DNA-PKCS depletion is equivalent to TNKS1 knockdown (in terms of 
depletion levels and depletion rate)37. Figure 5C illustrates the complete mechanism 
of XAV939-mediated inhibition of NHEJ. While enhanced gene targeting in the LIF 
3i XAV939-supplemented background (compared to the bFGF primed background) 
needs validation, it is interesting to note that the naturally occurring plant-derived 
compound vanillin (4-hydroxy-3-methoxybenzaldehyde), when administered in 
combination with recombinant adeno-associated viral (rAAV) vectors, acts to 
increase gene targeting frequencies by 10-fold compared to control rAAV 
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administrations55. Derived from the pods of Vanilla planifolia, Vanilla tahitensis and 
Vanilla pompon, vanillin also acts to inhibit NHEJ by directly inhibiting DNA-
PKCS56. The fact that vanillin sensitizes cells to the toxic effects of DNA-damaging 
agents57 and is an effective antimutagenic agent58–61 speaks to the notion that NHEJ is 
globally inhibited upon DNA-PKCS inhibition. XAV939 has the potential to have the 
same effect as vanillin to improve plasmid-based integration frequencies in LIF 3i 
converted hPSCs (Figure 5C). 
 
Using rhesus PSCs in blastocyst complementation experiments 
	  
In the near future, the use of non-human primate naïve PSCs in blastocyst 
complementation experiments62 will take us one step closer to generating human 
organs in organogenesis-disabled livestock (Figure 6A). By injecting patient-specific 
iPSCs into knockout-blastocysts from livestock (i.e. Pdx1-disabled blastocysts; Pdx1 
functions as a master regulator of pancreatic development), patient-specific iPSCs 
may complement the deficiency in an interspecies chimera and the newly formed 
organ (i.e. the pancreas in this example), would be composed entirely of genetically-
matched patient cells ready for harvest and patient transplantation. While blood 
vessels, nerves, and interstitial cells may be chimerized between host and donor cells, 
perhaps by further engineering double or triple knockout blastocysts to prevent the 
formation of host vasculature or nerves, these issues could possibly be solved. As an 
alternative to blastocyst complementation, Nakauchi and colleagues propose of in 
utero conceptus complementation, where temporospatial-specific injection of 
committed progenitor cells generated by in vitro directed differentiation could allow 
complementation of organ deficiency without risk of any off-target effects62 (Figure 
6B). In particular, naïve pluripotency provides a further advantage by possibly 
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mediating the generation of high quality committed progenitors after in vitro 
differentiation (compared to lineage-skewed primed PSCs). 
 
While these experiments may seem far off, naïve pluripotency has brought us closer 
to realizing the generation of interspecies chimeras. Current non-rodent PSCs of the 
epiblast-like primed variety are unable to contribute to chimeric animals. Mitalipov 
and colleagues have shown that injection of primed rhesus ESCs into blastocysts fails 
to produce chimeric offspring (they did, however, show that whole four-cell embryo 
aggregation of totipotent cells can result in the generation of chimeric monkeys)63. 
Using transgene-free naïve iPSCs arrested at an ICM-like stage of development with 
specific signaling inhibitors and stimulation of LIF/STAT signaling solves the issue 
of primed cells failing to contribute to chimeric offspring. 
 
If previous experiments are any indications of success (rat-mouse chimera-generated 
pancreas64, mouse-mouse chimera-generated kidney65, rat-mouse chimera-generated 
thymus66, pig-pig chimera-generated pancreas67, and mouse-mouse chimera-generated 
pancreas68), a functional whole organ composed of rhesus macaque tissue grown in a 
livestock animal will be demonstrated soon. While issues of organ vasculature, 
immune rejection, and various ethical challenges must be addressed, the potential of 
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Hypothesis and Objectives 
 
Given the widespread regenerative potential for authentic ground state rhesus PSCs, 
our group has recently turned to converting rhesus ESCs into a stable naïve state. 
Unpublished experiments indicate that LIF 3i reversion is insufficient to convert 
rhesus macaque ESC to a stable ground state, and therefore, further experimentation 
is required to optimize culture conditions. Here I investigate new in vitro culture 
conditions to support ground state growth of three rhesus macaque cell lines: 
ORMES-22 rhesus ESCs69, CRES-2 rhesus ESCs derived from somatic cell nuclear 
transfer (SCNT)70 and rhesus ESCs derived via parthenogenesis (rPESCs)71. Given 
recent evidence that singular blocking of vascular endothelial growth factor (VEGF) 
signaling with sunitinib malate (SU) promotes undifferentiated mouse ESC self-
renewal in the absence of feeder cells or LIF72, I hypothesize that blocking VEGF 
signaling in rhesus ESCs may reinforce mouse-like self-renewal. Additionally, to 
further confirm validity of a stable human ground state, I report microarray analysis 
of DNA double-strand break repair pathways in naïve human cells, together with 
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RESULTS 
 
Primed rhesus embryonic stem cells (ORMES-22) display unstable morphology 
and pronounced tendencies to spontaneously differentiate in basic fibroblast 
growth factor-supplemented knockout serum media 
 
ORMES-22 rESCs derived from in vitro fertilization were cultured on mitotically 
inactivated mouse embryonic fibroblasts (MEFs) in knockout serum replacement 
(KOSR) supplemented media with 20 ng/mL basic fibroblast growth factor (bFGF). 
These cells exhibited typical “primed” pluripotent characteristics. Colonies were flat 
and exhibited pronounced tendencies to spontaneously differentiate towards 
fibroblastic lineages (Figure 7). Compared to CRES-2 SCNT and rPESC lines 
cultured under identical primed bFGF-conditions with KOSR, the ORMES-22 line 
displayed most instability (Figure 7). Over the course of spontaneous differentiation, 
the rESCs exhibited reduced expression of surface pluripotency markers TRA-1-81, 
TRA-1-60, and SSEA-4, as measured by flow cytometry (personal correspondence, 
LZ). The cells were cultured under low O2 hypoxic conditions and manually passaged 
in colony clumps with the addition of 10 𝜇M rho-associated protein kinase (ROCK) 
inhibitor (Stemolecule Y27632). Partial-single cell dissociation during passaging 
resulted in pronounced differentiation and cell death even with the addition of ROCK 
inhibitor (data not shown). Given the unstable nature of the ORMES-22 rESCs, 
conversion to a naïve ground state would dramatically enhance ease of in vitro culture 
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ORMES-22 rESCs convert inefficiently to a naïve ground state of pluripotency 
with LIF 3i and LIF 5i cocktails 
 
Given that the large majority of permissive human PSC donors (high fidelity stromal 
primed cord blood iPSC and H9 ESC lines) could convert efficiently with LIF 3i or 
LIF 5i cocktails (see below for cocktail compositions), we tested the potential of these 
small molecule combinations to convert ORMES-22 rESCs to an authentic naïve 
ground state. In order to test whether our minimal inhibitor cocktail of human LIF, 
supplemented with GSK-3 𝛽  inhibitor (CHIR99021), MEK/ERK inhibitor 
(PD03259010) and WNT modulator XAV939 (collectively termed LIF 3i) would 
support the growth and derivation of naïve-like rESCs, high quality primed cells 
cultured to confluency over many passages were single cell dissociated with Accutase 
and cultured in LIF 3i. Over the course of 12 passages, the cells showed poor 
morphology and slow proliferation (Figure 8A-left). To examine whether a single 
passage of LIF 3i supplemented with two additional inhibitors (forskolin and 
purmorphamine - collectively now termed LIF 5i) would improve self-renewal, 
primed rESCs were converted with one passage of LIF 5i and then cultured thereafter 
continuously in LIF 3i. Cells showed improved morphology and growth but still 
displayed weak single cell cloning (Figure 8A-right). While morphology was good, 
the cells displayed reduced TRA-1-81, TRA-1-60, and SSEA-4 (personal 
correspondence, LZ) but still expressed the naïve markers Stella/DPPA3 and NR5A2 
(personal correspondence, LZ). This indicates that even when supplemented with the 
protein kinase A pathway agonist forskolin (which acts to induce KLF4 and KLF2 
expression9), and the hedgehog activator purmorphamine, molecules collectively 
expected to block differentiation and support self-renewal, the converted rESCs could 
not classically self-renew. Furthermore, direct conversion of ORMES-22 rESCs with 
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LIF 5i resulted in noted monolayer fibroblastic-like differentiation after 4-5 passages 
post single cell dissociation and culture in LIF 5i (personal correspondence, LZ). 
 
Optimization of culture conditions to support naïve-like self-renewal of rhesus 
embryonic stem cells with recombinant growth factors 
 
Given that direct LIF 3i, combined LIF 5i to LIF 3i, or direct LIF 5i conversion 
attempts with ORMES-22 rESCs were primarily unsuccessful owing to weak self-
renewal and unstable retention of phenotypic pluripotency over long-term culture 
(greater than 5 passages post conversion), I attempted to optimize growth of 
converted rESCs with recombinant growth factors above basal LIF 3i media. LIF 3i 
culture media was supplemented with further recombinant growth factors to examine 
whether the converted rESCs could be resurrected from a state of weak self-renewal. 
Given evidence that hypoxia promotes PSC renewal73, and the fact that primed 
ORMES-22 cells are conventionally cultured under low oxygen tensions, the addition 
of bFGF and BMP4 was examined under both normoxic and hypoxic conditions. The 
addition of bFGF greatly improved cell growth more than 3-fold under normoxic 
conditions and near 5-fold under hypoxic conditions (Figure 8B). The 
microenvironment ‘niche’ effect produced by hypoxia and the addition of bFGF is not 
surprising: conventional primed rESCs proliferate freely under low oxygen tensions. 
The fact that after LIF 5i to LIF 3i conversion and continued passaging in LIF 3i the 
cells do not respond to either hypoxia (without additional growth factors) or BMP4 
(Figure 8B) indicates that the addition of bFGF probably converts the cells into a 
quasi-naïve or “super” primed state, from which they respond significantly to hypoxia 
(as do ORMES-22 primed rESCs). Notably, LIF 3i-converted human pluripotent stem 
cells are BMP4-responsive and classically naïve (unpublished data, 2015). 
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Use of the anti-cancer drug, sunitinib malate, supports naïve-like self-renewal of 
converted ORMES-22 rESCs 
 
In an effort to definitively resurrect the converted rESCs without primed growth 
factors (i.e. bFGF, SCF, TGF-𝛽), I reasoned that combined inhibition of various 
receptor tyrosine kinases (RTKs) including VEGF receptor and PDGF receptor would 
promote naïve-like self-renewal (given that singular blocking of VEGF signaling 
promotes undifferentiated mouse ESC self-renewal in the absence of feeder cells or 
LIF72). The chosen molecule sunitinib malate (SU11248 or SU), a potent inhibitor of 
VEGF receptor, PDGF receptor, KIT, FLT3 and RET, was tested on top of LIF 3i 
under normoxic and hypoxic conditions.  LIF 3i plus 1 𝜇M sunitinib (termed LIF 4i) 
produced improved single cell growth under hypoxic conditions (Figure 8C), which 
is interesting considering that hypoxia inducible factor-1 alpha (HIF-1𝛼 ) lies 
downstream of VEGF receptor. Removal of LIF in LIF 4i conditions (termed 4i 
alone), showed improved but weak growth under hypoxia versus the control LIF 3i 
(Figure 8C).  
 
Conversion of ORMES-22 rESCs with one passage of LIF 5i and subsequent 
passaging in LIF 4i supports robust naïve-like self-renewal 
 
In order to assess the efficacy of SU and the GSK3𝛽 inhibitor lithium chloride74, fresh 
primed bFGF-dependent rESCs were converted with one passage of LIF 5i and then 
cultured in either LIF 3i, LIF 4i, LIF 3i plus lithium chloride, or LIF 4i plus lithium 
chloride (all under hypoxic conditions). Figure 9A details a general conversion 
protocol. After one passage in LIF 5i, the ORMES-22 rESCs displayed naïve-like 
dome-shaped morphology and proficient growth (Figure 9B). However, the cells 
displayed weak TRA-1-81 expression as determined by flow cytometry, and low 
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SSEA-4 expression on the order of 10% SSEA-4+ cells (Figure 9Fi, G). A switch to 
either LIF 3i or LIF 4i did not improve SSEA-4 surface marker expression, which fell 
to almost zero after 2 passages in either LIF 3i or LIF 4i (Figure 9Fii, Fiii, G). 
Despite this, cell growth was markedly improved in LIF 4i conditions compared to 
the other tested culture conditions (Figure 9C). It appears that the addition of 1 𝜇M 
sunitinib was keeping the converted cells in a proliferative state, even after the stress 
of single cell dissociation. Growth in LIF 4i appeared to have an improved effect after 
the second passage, with an improved rate of growth (Figure 9D). 
 
While the converted cells cultured in LIF 3i or LIF 4i displayed reduced expression of 
pluripotency surface markers, it is possible that the human conjugated antibodies used 
for flow cytometry were not reacting to the markers on rhesus cells. Additionally, it is 
possible that the starting population of bFGF-dependent cells were already in the 
process of differentiation prior to conversion. Therefore, to assay pluripotency further, 
converted cells cultured in LIF 3i or LIF 4i were examined for expression of alkaline 
phosphatase. All pluripotent stem cells exhibit elevated expression of alkaline 
phosphatase. While some ORMES-22 LIF 5i to LIF 3i rESCs stained positive for 
alkaline phosphatase (Figure 9E-centre), most of these colonies displayed 
differentiated morphologies and so were regarded as false positives (Figure 9E-
centre). ORMES-22 LIF 5i to LIF 4i rESCs displayed robust staining for alkaline 
phosphatase and even small colonies stained positive (Figure 9E-right), highlighting 
that rESCs cultured in LIF 4i were highly clonogenic and undifferentiated. 
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Direct conversion of ORMES-22 rESCs with an alternative LIF 3i cocktail 
supports improved self-renewal and retention of phenotypic pluripotency 
 
For naïve pluripotency to have an immediate impact on regenerative medicine 
clinically, naïve conversion protocols must be simple, uncontrived, and efficient. As 
such, direct conversion of PSCs with unique minimal inhibitor cocktails is desirable 
to ensure widespread protocol adoption in translational research or therapy. In order 
to examine whether LIF 5i-initial conversion was dispensable, I converted ORMES-
22 cells directly using 12 different conditions (6 conditions under normoxia and 6 
conditions under hypoxia; Figure 10A). Most notably, an alternative LIF 3i (with 
CHIR, PD, and SU) under normoxic conditions supported the highest growth rates 
(Figure 10A). Cells under similar conditions under hypoxia showed slower growth 
rates but better morphology after one passage (Figure 10B). However, given the rapid 
growth rates under normoxic LIF CHIR-PD-SU conditions, it is possible that this 
condition promotes discreet differentiation of the ORMES-22 cells. Indeed, at passage 
2, this alternative LIF 3i combination appears to have promoted differentiation under 
both normoxia and hypoxia (Figure 10C), as evidenced by monolayer-like 
morphology and little to no SSEA-4 surface marker expression (Figure 10D). 
Interestingly, classical LIF 2i showed good growth kinetics over two passages 
(Figure 10A, E) and surprisingly good morphology (Figure 10B, C). However, this 
condition also resulted in poor SSEA-4 expression (Figure 10D). At this stage of the 
experiment, the novel secondary LIF 3i (LIF XAV-PD-SU) under normoxia appears 
to have moderate growth rates, but importantly seems to cause strong retention of 
SSEA-4 expression (Figure 10D). Note that hypoxia appears to buffer the growth 
kinetics seen across the six culture conditions versus normoxia (tighter distribution of 
curves in Figure 10E-right compared to normoxia in Figure 10E-left). 
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Direct conversion of alternative rhesus ESC lines favors LIF 4i reversion 
 
CRES-2 SCNT rESCs together with parthenogenesis-derived rPESCs were also 
converted directly without LIF 5i to determine if particular rESC lines are more 
permissive to naïve reversion than others. CRES-2 cells showed poor growth and 
weak SSEA-4 expression under hypoxic LIF 3i or LIF 4i conditions (Figure 11A, B, 
C, D), while rPESCs showed stronger growth and moderate SSEA-4 expression under 
LIF 4i compared to LIF 3i (Figure 11A, B, C, D). This is confirmed by the 
longitudinal examination of growth kinetics. At this stage, only the rPESC LIF 4i line 
appears to be expanding successfully (Figure 11E) compared to the three other 
experimental samples. 
 
Authentic LIF 3i-converted human ground state PSCs display characteristic 
hallmarks of a stable naïve state 
 
LIF 3i-converted ground state PSCs display activated homologous recombination 
machinery as determined by gene set enrichment analysis 
	  
In order to examine whether conversion to a naïve state of pluripotency may support 
more efficient gene targeting via homologous recombination (HR), gene set 
enrichment analysis (GSEA)75 of gene expression array data was employed. Illumina 
HumanHT-12 arrays previously conducted on 12 different naïve ESC and iPSC lines, 
together with their primed source cells (from Zimmerlin et al.), were analyzed to 
examine differences in HR genes and NHEJ genes. GSEA is a bioinformatics 
computation that examines whether an a priori defined set of genes shows statistically 
significant differences between two different biological states (here naïve vs. primed). 
HR pathway genes were upregulated in the naïve state with a normalized enrichment 
score (NES) of 1.42 with a significant p value < 0.05 for all lines (Figure 12A). 
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Notably, stromal primed cord blood iPSC lines appear to show the most robust 
upregulation of HR pathway genes in the naïve state. NHEJ pathway genes were also 
upregulated with an NES of 0.95 in the naïve state, however this result was not 
statistically significant (Figure 12B). This indicates that the naïve ground state in 
human pluripotent stem cells is potentially amenable to support more efficient 
plasmid-based gene targeting via endogenously-activated HR machinery. 
 
DNA methylation does not mechanistically contribute to a potential proximal to distal 
enhancer regulatory switch driving OCT4 expression 
	  
Given that the distal enhancer of OCT4 predominantly drives OCT4 expression in the 
naïve state, I sought to investigate whether LIF 3i converted human cells displayed 
DNA methylation changes across the distal or proximal enhancers in comparison to 
bFGF source cells. While it is likely that a combination of histone modifications and 
DNA methylation changes drive the switch from proximal to distal enhancer 
regulation during the primed to naïve transition, DNA methylation may play a 
dominant mechanistic role in this transition. Previously conducted Infinium 450k 
methylation arrays from the work of Zimmerlin et al. (2015) were probed to examine 
any DNA methylation differences across the OCT4 proximal or distal enhancer 
between naïve and primed human PSC lines. As defined by Zimmerlin et al. (2015), 
“high performing lines” were human ESC and stromal-primed myeloid progenitor 
iPSC primed lines that converted efficiently with LIF 3i as measured by naive growth 
characteristics, retention of phenotypic pluripotency, and naïve hallmarks. “Low 
performing lines” were fibroblast iPSC primed lines that converted inefficiently with 
LIF 3i as measured by the above criteria. The Infinium 450k array provides six CpG 
probes in the proximal enhancer, and three probes in the distal enhancer (Figure 13). 
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Note that the proximal and distal enhancer coordinates along human chromosome 6 
were extracted using sequence homology to two luciferase proximal enhancer and 
distal enhancer constructs (see Gafni et al.21). These constructs will be used in a future 
functional OCT4 enhancer predominance assay and it was important for us to 
examine methylation profiles at endogenous sequences that paralleled sequences 
found in OCT4 luciferase enhancer vectors. This way, any differences in downstream 
results (from DNA methylation profiling versus functional profiling with luciferase 
constructs) can be appropriately compared given that the endogenous enhancer 
sequences and construct enhancer sequences perfectly align. Unexpectedly, for both 
high performing lines and low performing lines, the bFGF primed source cells on 
average displayed greater methylation at the proximal enhancer compared to LIF 3i 
cells (Figure 13). However, it is interesting to note that at CpG sites 5 and 6, low 
performing LIF 3i lines display higher methylation levels at the proximal enhancer 
(which is somewhat indicative of a putative naïve state). At the distal enhancer, the 
methylation profile is more indicative of the naïve state. Both high performing and 
low performing LIF 3i lines display reduced methylation versus their bFGF source 
counterparts, indicating some level of distal enhancer activity. While experiments 
such as ChIP-PCR or DNase I hypersensitivity assays will allow further examination 
into OCT4 enhancer regulation, functional assessment of enhancer predominance (i.e. 
through luciferase reporter constructs) is needed to fully conclude whether or not LIF 
3i human conversion results in the typical proximal to distal enhancer switch. 
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DISCUSSION 
 
Are certain PSC donors more receptive to naïve reversion than others? 
 
Considering the fact that select human stromal primed cord blood iPSC lines revert 
more efficiently to a naïve state with LIF 3i compared to fibroblast iPSC (unpublished 
data, 2015), we can establish that receptiveness to naïve reversion is line-dependent. 
This may stretch across species. Indeed, in vitro phenotypic and molecular 
heterogeneity coupled with interline variability dominates the culture of mouse, 
human, and rhesus macaque pluripotent stem cell (PSC) culture. As measured by 
defined performance metrics for pluripotency (including differentiation potency and 
phenotypic and functional pluripotency), studies have identified (notably in human 
cells) that it is unclear whether unique genetic or epigenetic differences between ESC 
lines76–79 and iPSC lines80–84 contributes to variability. Presumably, distinct derivation 
methods, culture reagents, passaging techniques, choice of mitotically inactivated 
feeder cells, and atmospheric conditions used to expand PSCs causes unique cell lines 
to fall within distinct brackets on the classically defined epigenetic continuum of 
differentiation first described by Conrad Waddington in 195785,86. Simply, 
receptiveness to naïve reversion may depend on a starting cell’s “epigenetic distance” 
from the canonical ground state. 
 
At the top of Waddington’s landscape we find the ground state of PSC self-renewal 
(LIF/JAK/STAT3, BMP4 responsive3,32,87,88), and following a further committed 
trajectory downhill, the primed PSC state of self-renewal (bFGF, Activin A 
responsive). Given the complex cocktails of primed growth factors and viability 
enhancers used to sustain supposedly naïve mouse-ESC-like human pluripotency, and 
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the recent report of rhesus macaque naïve iPSCs converted with LIF 2i/bFGF27, it is 
possible that human and non-human primate primed PSCs are “non-permissive” to 
conversion to a canonical ground-state defined by mouse-ESCs. However, our lab has 
recently shown that stromal-primed STAT3-activated human CD33+CD45+ myeloid 
progenitors reprogrammed to a state of induced pluripotency with little to no 
reprogramming aberrations are amenable to ground-state reversion with LIF 2i 
supplemented with XAV939. Given this and further evidence that PSCs 
reprogrammed from somatic cells may assume distinct pluripotent states within the 
upper echelons of Waddington’s epigenetic landscape89, it is clear that species-
specific differences are not the only reasons for the previously difficult conversion of 
human and non-human primate PSCs into a BMP4 responsive ground state. 
 
Data presented indicates that the ORMES-22 rESC line used in this study is non-
permissive to minimal-cocktail naïve reversion. The line was derived in fetal bovine 
serum (FBS) culture media69 and definitively requires high concentrations of bFGF to 
eliminate spontaneous differentiation. Upon receipt of the line from Shoukhrat 
Mitalipov, our lab adapted the line to knockout serum replacement (KOSR).  It is 
possible then, that the primed ORMES-22 line requires growth factors present in FBS 
(which are absent in knockout serum) to proliferate in a continued undifferentiated 
state. ORMES-22 primed rESCs will likely need to be cultured in FBS-supplemented 
media over multiple passages (>10) to realize whether the cells are experiencing an 
FBS-deficiency after KOSR adaptation. 
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Reaching a naïve ground state of pluripotency for rhesus PSCs 
 
Previous conversion attempts in our lab with LIF 3i or LIF 5i have shown that the 
ORMES-22 line shows growth kinetics that aligns with previously defined non-
permissive hESC lines (including H7 and ES03). Interestingly, unpublished 
bioinformatics analyses of global transcriptional profiles do not reveal any striking 
reason for why the H7 and ES03 hESC lines convert inefficiently with LIF 3i or LIF 
5i (personal correspondence, LZ and JH). Given that LIF 3i/LIF 5i-converted 
ORMES-22 rESCs are non-BMP4 responsive and weakly proliferative, I reasoned 
that combined inhibition of various receptor tyrosine kinases (RTKs) including VEGF 
receptor and PDGF receptor would promote naïve-like self-renewal. Sunitinib malate 
(in combination with LIF 3i or LIF-XAV-PD) was a robust addition to our minimal 
naïve cocktail. While it is mechanistically unclear at this stage why sunitinib malate 
promotes naïve-like growth in rhesus ESCs, global VEGF receptor inhibition may 
prove to be important for attaining a stable mouse ESC-like state in non-permissive 
PSC donors (including rhesus and human non-permissive PSC lines). Indeed, Chen et 
al. demonstrate that sunitinib malate alone promotes undifferentiated mouse ESC self-
renewal in the absence of feeder cells or LIF, and such a ‘1i’ cocktail without LIF 
supports mouse ESC self-renewal as successfully as classical Austin Smith LIF 2i72. 
Chen and colleagues further show that their 1i cocktail facilitates the de novo 
derivation of mouse ESCs from blastocysts that later contribute to chimeric mice72. 
Remarkably, they also show that 1 𝜇M sunitinib-containing medium facilitates the 
generation of iPSCs from mouse embryonic fibroblasts (MEFs) with only one factor 
(OCT4)72. Ultimately then, it will be valuable to further investigate a possible role for 
VEGF receptor inhibition in rhesus and human ground state self-renewal. On the 
human front, the potential of sunitinib to promote human naïve pluripotency has been 
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investigated by Jaenisch and colleagues and presented as supplemental data (see 
Theunissen et al. 2014). After engineering OCT4-2A-GFP reporter human ESC with a 
deletion of the OCT4 proximal enhancer (∆PE), Theunissen et al. identify OCT4-
∆PE-GFP+ cells with sunitinib during their high-throughput kinase inhibitor screen to 
identify small molecules that promote naïve human pluripotency25. While they do not 
incorporate sunitinib into their cocktail of 5i/L/A (MEKi, GSK3𝛽i, ROCKi, BRAFi, 
LCK/SRCi90, hLIF, Activin A), sunitinib malate was strongly identified during their 
screen for inhibitors that support human naïve pluripotency. After doxycycline-
withdrawal of KLF2 and NANOG transgene expression in their engineered reporter 
lines, they identify SU11248 (sunitinib) on top of LIF 2i plus the BRAF inhibitor 
SB59088525. While it seems that BRAF inhibition synergizes with LIF 2i/sunitinib to 
produce human OCT4-∆PE-GFP+ cells (LIF 2i/sunitinib alone does not produce 
OCT4-∆PE-GFP+ cells25), the use of XAV939 may synergistically replace BRAF 
inhibition for the better in our attempt to induce rhesus naïve pluripotency. Indeed, 
XAV939 and sunitinib  (together with LIF 2i) may prove useful for human naïve 
pluripotency. 
 
Mechanistically, why might VEGF receptor inhibition promote mouse ESC-like self-
renewal in rhesus ESCs? Presumably, the stress of single cell dissociation in 
combination with hypoxia stimulates the secretion of vascular endothelial growth 
factor (VEGF) molecules into the immediate in vitro culture environment. This is 
likely to occur via activation of an endoplasmic reticulum (ER) stress/HIF-1𝛼 
sigalling axis72. Indeed, I suspect that this is the reason for notable spontaneous 
differentiation seen in ORMES-22 primed cultures grown with hypoxia. While 
evidence suggests that hypoxia may be beneficial for the undifferentiated propagation 
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of rESC69,91 and human ESC cultures92, other groups have reported vascular-lineage 
priming of mouse ESCs with hypoxia (via HIF1-dependent mechanisms)93,94.  In this 
regard, hypoxia may act somewhat like a double-edged sword: it may simultaneously 
promote 𝛽-catenin activation and enhance the self-renewal of PSCs95, but also may 
act to induce discreet vascular-lineage differentiation. Here, inhibiting VEGF receptor 
(in particular) with sunitinib malate may not only suppress stress/hypoxia induced 
differentiation, but fortify the combined effect of LIF 2i for the following two 
reasons: (1) LIF/LIF receptor/gp130 activation has a secondary effect of supposedly 
inhibiting HIF-1𝛼/ER stress activation and subsequent secretion of VEGF72,96; and (2) 
GSK-3𝛽  and MEK/ERK lie downstream of VEGF/VEGF receptor activation to 
reinforce the effect of CHIR99021 and PD0325901 (Figure 14). 
 
To investigate whether the naïve cocktail of LIF 5i is dispensable for naïve rhesus 
reversion, fresh primed rESCs were converted with six chemical combinations of LIF, 
CHIR, PD, XAV, and SU (under both normoxic and hypoxic conditions). 
Surprisingly, the condition of normoxic LIF CHIR-PD-SU provided the greatest 
growth rates, but unfortunately, this condition appeared to differentiate the converted 
cells. While the normoxic condition of LIF XAV-PD-SU showed moderate growth 
kinetics, SSEA-4 expression as assessed via live staining was robust. Given that 
hypoxia promotes murine autocrine VEGF signalling72, it appears that SU effectively 
does not have to work as much against VEGF ligands under normoxic conditions and 
therefore has a greater effect without hypoxia. While hypoxia stimulates active 𝛽-
catenin in pluripotent stem cells95 and promotes stem/progenitor cell enrichment97, it 
may have secondary undesirable consequences for naïve (or primed) rhesus growth. 
In fact, I am currently examining whether addition of a blocking antibody to VEGF 
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receptor 2 can prevent the typical spontaneous differentiation seen in primed 
ORMES-22 rESCs. If selectively blocking VEGF receptor 2 maintains hypoxic 
primed ORMES-22 cells in a prolonged undifferentiated state, it may indicate that 
indeed hypoxia promotes VEGF secretion in rESCs. In support of hypoxia promoting 
active 𝛽-catenin, conversion of ORMES-22 rESCs with hypoxia did seem to buffer 
all six chemical conditions towards a similar growth trajectory compared to normoxia 
(Figure 10E), indicating the intrinsic potential of hypoxia to promote PSC self-
renewal. However, hypoxic conversion for the ORMES-22 line appears to promote 
differentiation by passage 2 for most chemical combinations of inhibitors tested 
(Figure 10B, C, D).  
 
Lastly, conversion of alternative CRES-2 SCNT and rPESC lines did not result in 
more efficient growth kinetics or SSEA-4 retention compared to the ORMES-22 line. 
It is likely that high-quality, transiently undifferentiated, primed cells are required for 
effective conversion efficiencies for these two alternative rhesus lines. 
 
Examination of characteristic hallmarks for ground state pluripotency in LIF-3i 
converted human PSCs 
 
In order to further validate that LIF 3i converted “permissive” human iPSCs were 
classically naïve, further hallmarks of the naïve state were investigated. While the 
DNA methylation profile seen across the OCT4 distal enhancer was consistent with 
the naïve state, the OCT4 proximal enhancer methylation profile was inconclusive. 
However, LIF 3i human naïve PSCs displayed a statistically significant upregulation 
of homologous recombination (HR) genes (as assessed by GSEA) compared to their 
primed source counterparts. This is an exciting result for future gene targeting 
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experiments. Plasmid-based gene editing via HR may be greatly improved in the 
naïve state. Additionally, since current genome editing technologies creating synthetic 
double-strand breaks (i.e. ZFNs, TALENs, and CRISPR/Cas9 nucleases) also employ 
endogenous HR machinery to create sequence-specific edits with a donor vector, if 
these technologies were employed using the naïve pluripotent platform, gene targeting 
efficiencies could be significantly magnified (consider that HR-only mouse-ESC 
efficiencies are on the order of 20%). The upregulation of HR machinery genes could 
be beneficial for isogenic gene targeting as well, and it is likely that only one arm of a 
targeting vector would need to be sequence matched/PCR amplified from genomic 
DNA of host cells to result in an efficient biallelic genome editing event. Correction 
of sickle cell anemia and beta thalassemia mutations in patient-specific naïve iPSCs 
using the seamless genome-editing advantage of the PiggyBac transposon98–102 is a 
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CONCLUSIONS AND PERSPECTIVES 
 
Interrogation of naïve PSC self-renewal has shed tremendous light on a previously 
enigmatic state. Large-scale computational syntheses of ChIP-seq and microarray data 
has uncovered core transcription factor interactions in the ground state103 and a 
computational synthesis of transcriptome data has revealed the validity of various 
naïve culture cocktails104; in essence, confirming our improved progress towards 
understanding the naïve ground state. Once further evidence accumulates that naïve 
PSCs possess improved differentiation potencies and enhanced amenability to 
plasmid-based HR over their primed counterparts, naïve pluripotent cell biology will 
be at the forefront of regenerative medicine. Beyond in vitro systems, blastocyst 
complementation experiments represent the most powerful application of ground state 
non-human primate and human PSCs. It is remarkable that via simple signaling 
inhibition and cytokine stimulation PSCs can be arrested in an ICM-like fate in vitro; 
it highlights that biological states once enigmatic, can be controllable after extensive 
and systematic mechanistic investigations. With each new study, it is evident that the 
methodological impact of naïve PSCs in stem cell biology and regenerative medicine 
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MATERIALS AND METHODS 
 
Culture of mouse embryonic fibroblasts (MEFs) 
 
MEF cells at passage 2 were cultured for one week in two 0.1 % gelatinized T175 
flasks, trypsinized (TrypLE Select, Gibco), counted, and split into ten T175 flasks for 
expansion at passage 3. MEF medium included: ~ 90% DMEM (Invitrogen) 
supplemented with ~10% FBS, 0.1 mM MEM non-essential amino acids (Gibco), L-
glutamine to a final concentration of 2mM (Gibco), 0.1 mM β-mercaptoethanol 
(Sigma) and penicillin/streptomycin (Gibco). Cells were harvested and irradiated for 
mitotic inactivation at 5000 rad. Cells not needed immediately were cryopreserved. 
 
Culture of primed rhesus monkey embryonic stem cells (rESCs) 
 
All primed pluripotent stem cell lines used in this study were co-cultured on irradiated 
DR4 MEF feeders and incubated under hypoxic conditions at 37°C, 5% CO2 and 85% 
relative humidity (unless otherwise indicated). Cells were fed daily and maintained 
with regular hESC medium consisting of ~80% DMEM/F12 (Invitrogen) medium 
supplemented with ~20% Knockout Serum Replacement (KOSR; Invitrogen), 0.1 
mM MEM non-essential amino acids (Gibco), L-glutamine to a final concentration of 
1mM (Gibco), 0.1 mM β-mercaptoethanol (Sigma) and FGF2 to a final concentration 
of 20 ng/mL (R&D systems). Cells were both manually passaged (using a pipette 
above an inverted microscope to manually detach and select hESCs colonies with 
good morphology -- sharp edges, homogenous interior, shiny non-dark surface) and 
passaged in bulk using a cell scraper to detach pluripotent stem cells. Both protocols 
involved a 5min collagenase digestion at 37°C to loosen colonies prior to detachment.  
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Culture of naïve rhesus monkey embryonic stem cells (rESCs) 
 
“Naïve” culture conditions for ground-state pluripotency included the addition of 
various cytokines and small molecule inhibitors. Cells were alternatively cultured 
under normoxia or hypoxia with DR4 MEF feeders and fed daily (to compensate for 
the short half-life of small molecules employed). All naïve formulations consisted of 
basal KOSR-based hESC medium without bFGF (unless otherwise indicated). The 
following cytokines and small molecules (with optimal working concentrations) were 
used in various combinations throughout this study: human LIF (20ng/mL, 
alternatively purchased from Sigma, cat no. L5283, Cell Signaling, cat no. 8911LC, 
or Peprotech, cat no. 300-05), PD0325901 (1µM, Stemgent, cat no. 040006 or Sigma, 
cat no. PZ0162), CHIR99021 (3µM, Stemgent, cat no. 04-0004 or Tocris Bioscience, 
cat no. 4423), XAV939 (4µM, Sigma, cat no. X3004), Forskolin (10µM, Stemgent, 
cat no. 04-0025), Purmorphamine (2µM, Stemgent, cat no. 04-0009), Sunitinib malate 
(1µM, Sigma, cat no. PZ0012), lithium chloride (10mM, Sigma, cat no. 298328), and 
BMP4 (10ng/mL, Peprotech). Additionally, where indicated, ROCK inhibitor was 
also used at 10µM (Stemolecule Y27632, Stemgent, cat no. 04-0012). Conversion of 
primed bFGF lines consisted of a 48-hour adaptation step followed by single cell 
dissociation using StemPro Accutase cell detachment solution (Life Technologies). 
Single cells were re-plated at densities between 50,000 to 100,000 cells/cm2. All cell 
cultures were counted with a Countess Cell Counter (Life Technologies) via trypan 
blue exclusion. Cultures were examined with phase contrast microscopy using an 
Eclipse TE-2000 inverted microscope (Nikon Instruments) equipped with a DS-Fi1 
camera and NIS-Elements software (Nikon Instruments). Note: conventional LIF 3i 
consists of human LIF, plus three small molecule inhibitors: CHIR99021 (GSK3𝛽i), 
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PD0325901 (MEK/ERKi), and XAV939 (WNT modulator). LIF 5i consists of LIF 3i 
plus forskolin and purmorphamine.  
 
Monitoring phenotypic pluripotency (flow cytometry, alkaline phosphatase 
staining, and live fluorescent staining) 
 
Retention of phenotypic pluripotency was measured by flow cytometry using anti-
human SSEA-4 (R&D) and TRA-1-81 (BD-Biosciences) antibodies. Primed and 
naïve cultures were briefly washed once in phosphate-buffered saline (PBS, Life 
Technologies) and dissociated using Accutase solution for 5 min at 37°C. After 
enzymatic neutralization, single cell suspensions were re-suspended in culture 
medium and counted using a Countess Cell Counter. After one wash in PBS, 100,000 
- 200,000 cell aliquots were incubated for 20 minutes at 4°C with monoclonal mouse 
antihuman antibodies SSEA4-APC (5µL, cat no. FAB1435A, R&D Systems) and 
TRA-1-81-PE (10µL, cat no. 560161, BD-Biosciences). Isotype controls matching 
each immunoglobulin subtype were stained analogously to measure non-specific 
binding. To quantitatively measure SSEA-4+ or TRA-1-81+ cells, exactly 10,000 
events per sample (at a rate below 300 events per second) were acquired using a dual 
laser FACSCalibur flow cytometer (BD-Biosciences) equipped with blue argon (488 
nm) and red diode (635 nm) lasers and the BD CellQuest Pro analytical software 
(BD-Biosciences). Analysis was conducted using FlowJo single cell FACS software 
(Tree Star). 
 
To conduct alkaline phosphatase staining, cultures were gently fixed in 2% PBS/ 
paraformaldehyde (Affymetrix) for 10 minutes, washed with PBS, and stained with 
BCIP/NBT substrate (Life Technologies) for 10-15 min at room temperature. 
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Reactions were stopped after 15 minutes and wells were subsequently washed twice 
with PBS and imaged. 
 
Lastly, live staining for SSEA-4 expression was conducted using a mouse anti-human 
SSEA-4 NL493-conjugated monoclonal antibody. Live cells were stained for 2 hours 
using 1x SSEA-4 NL493 antibody in cell culture medium and subsequently washed 
once with cell culture medium and once with PBS. The cells were examined using 
epifluorescence in 1x Live Cell Imaging Solution (Life Technologies). 
 
GSEA and Infinium DNA methylation array analysis 
 
KEGG (Kyoto Encyclopedia of Genes and Genomes) gene sets for homologous 
recombination (HR) and non-homologous end joining (NHEJ) were used for gene set 
enrichment analysis (GSEA). Normalized Illumina arrays from human LIF 3i naïve 
and bFGF source cell lines were probed for differences in HR or NHEJ pathway 
genes using online GSEA software (http://www.broadinstitute.org/gsea/index.jsp). To 
examine the DNA methylation profile across the human OCT4 proximal and distal 
enhancers, Infinium 450k methylation array data from human LIF 3i naïve and bFGF 
source lines was kindly provided by JH. Using sequence homology to luciferase 
vectors from Gafni et al.21, the human coordinates for the proximal and distal 
enhancers were extracted and aligned to CpG probes from the 450k methylation array. 
To locate probes within the enhancers, SnapGene software was used for sequence 
examination. Beta values at each probe were subsequently plotted using GraphPad 
Prism software. 
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Figure 1  ICM-like human pluripotent stem cells in a context of pluripotency. Pluripotent stem cells 
exist in either of two states: an ICM-like state (also called ‘naive’) or an epithelial epiblast–like state 
(also called ‘primed’). Only ICM-like pluripotent stem cells form dome-shaped colonies, have active 
X-chromosomes, are LIF-dependent and contribute to mouse morula/blastocyst chimeras (Table 1). Mouse 
embryonic stem cells (ICM-like) and epiblast stem cells (epithelial epiblast–like) can be interconverted 
by interchanging their medium conditions. All previously derived stable human embryonic stem cell lines 
are epithelial epiblast–like (flat colonies, X-inactivation, Activin + FGF dependent). Gafni et al.1 describe 
the first stable transgene-independent, ICM-like human pluripotent stem cells (red arrows), which they 
derived using a combination of exogenous factors (naive human stem cell medium, NHSM). The ICM-like 
human pluripotent stem cells appear to fulfill criteria for ICM-like mouse pluripotent stem cells, but this 










































insects, nor Xenopus of amphibia, mice are not 
a wholly representative model of mammals.
Indeed, species divergence between mice 
and humans has offered a ready source of 
explanations for the elusive nature of ICM-
like human pluripotent stem cells. Principally, 
the feasibility of deriving ICM-like mouse 
embryonic stem cells in vitro has been 
ascribed to a peri-implantation requirement 
for LIF/STAT signaling during diapause6, a 
developmental stage that is absent in humans. 
Intriguingly, the results of Gafni et al.1 prove 
that the absence of diapause in humans 
was not the reason for previous failures to 
derive ICM-like human pluripotent stem 
cells and reveal this to be another instance 
of mouse-shaped expectations misplaced on 
human development. 
In this context, it is curious that LIF/STAT 
signaling is essential for maintenance of 
NHSM-dependent pluripotency1. In a similar 
vein, Gafni et al.1 added both fibroblast growth 
factor (FGF) and simultaneously inhibited its 
downstream p38, JNK and ERK activities to 
maintain ICM-like  human pluripotent stem 
cells, whereas any one of these three inhibi-
tors alone prevents differentiation in mouse 
embryonic stem cells. These examples raise 
the question: where do ICM-like human pluri-
potent stem cells sit in the context of human 
development?
The lack of information about human 
embryogenesis is an obstacle to understanding 
how closely in vitro pluripotency and dif-
ferentiation of human pluripotent stem cells 
mimic normal development. Native pluri-
potent cells in the developing embryo exist 
transiently, whereas pluripotent stem cells can 
be maintained in vitro indefinitely. The most 
biologically relevant available comparator for 
ICM-like human pluripotent stem cells is the 
human ICM. Gafni et al.1 compared their ICM-
like human pluripotent stem cells with human 
ICM and conventional (epithelial epiblast–
like) human pluripotent stem cells by hierar-
chical clustering of their mean transcriptional 
profiles. The ICM-like pluripotent stem cells 
clustered with the ICM and were distinct from 
the epithelial epiblast–like cells, although they 
appeared to show 
less similarity com-
pared with clustering 
between two unre-
lated human epithelial 
epiblast–like datasets. 
It is significant 
that Gafni et al.1 
captured ICM-
like human pluri-
potent stem cells 
with characteristics 
similar to, but not the same as, the human 
ICM cells. This may reflect the known 
heterogeneity in the ICM or adaptation of 
cells to culture, or it may suggest that a 
pluripotent state could be derived in vitro 
with even greater similarity to the human 
ICM. This ambiguity underlines how much 
remains to be learned about both human 
stem cell pluripotency in vitro and early 
human embryogenesis to enable their pre-
cise alignment.
With this perspective, we suggest that the 
classification of pluripotency into ‘naive’ and 
‘primed’ states is an oversimplification that 
does not capture the full biological nature of 
pluripotency. The ‘primed’ classification derives 
from the finding that epithelial epiblast–like 
pluripotent stem cells express genes that are 
associated with differentiation into early cell 
lineages7. But these genes may also have roles in 
maintaining pluripotency, just as pluripotency-
 associated genes have key roles in lineage speci-
fication8. We therefore prefer terms based on 
the cellular structure of the embryo’s pluripo-
tent tissues: ICM-like and epithelial epiblast–
like. It should also be noted that classifications 
based on implantation status, namely, pre- and 
post-implantation, will not stand the test of 
species divergence: embryos of larger mam-








Table 1 Characteristics of pluripotent stem cell state
ICM-like Epithelial epiblast–like
Mouse embryonic stem cells Mouse epiblast stem cells
NHSM-derived human pluripotent 
stem cells
Conventional human pluripotent  
stem cells
Dome-shaped colonies Flat colonies
Reduced doubling time Increased doubling time
X-chromosomes active X-chromosomes inactivated
Single-cell cloning Poor single-cell cloning
Use of OCT4 distal enhancer Use of OCT4 proximal enhancer
ICM integration Low ICM integration
LIF-dependent Activin/FGF-dependent


























Figure 1: Species-specific contextual examination of naïve pluripotency between 
mice and humans 
 
In mice, epiblast stem cells corresponding to the egg cylinder stage of development 
depend on Activin and FGF signaling, while embryonic stem cells corresponding to 
the inner cell mass (ICM) of the blastocyst depend on LIF/STAT signaling (with 2i). 
Derivations from somatic cells, blastocysts, and egg cylinders are depicted, together 
with the reversible interconversion between primed and ground state pluripotency (via 
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transgene-free methods or transgene-dependent methods). Like in mice, ground state 
human embryonic stem cells may be isolated from the ICM when cultured in 
LIF/STAT-conducive media (with further signaling inhibitors), or primed cells may 
be isolated when cultured with Activin and FGF. Derivations from somatic cells and 
blastocysts are depicted, together with the interconversion between primed and 
ground state pluripotency (via transgene-free methods or transgene-dependent 
methods). Naïve medium refers to human embryonic stem cell medium supplemented 
with human LIF, MEK/ERK inhibition, GSK3𝛽 inhibition, and various other small 
molecule inhibitors and recombinant growth factors. Notably, work by Zimmerlin et 
al. only requires the addition of axin-stabilizing XAV939 above basal LIF 2i medium 
to convert primed human PSCs into ground state PSCs. Abbreviations: OSKM = 
OCT4, SOX2, KLF4, and c-MYC (the Yamanaka factors105). This figure is modified 






























Figure 2: The changing epigenetic and transcription factor landscape seen across 
the transition from naïve pluripotency to primed pluripotency 
 
(A) The transition through various stages of stem cell potency: naïve pluripotency; a 
reversibility phase; a transitional state; primed pluripotency, and finally lineage 
segregation. The stages of stem cell potency are depicted along Waddington’s 
Epigenetic Landscape, first proposed by C. H. Waddington in 1942. 
Waddington’s Landscape classically depicts the process of differentiation as a fall 
in “potential energy” (so to speak) and an increase in DNA methylation. Notice 




























Developmental progression from ground state embryonic stem (ES) cell to lineage commitment. On release from ground state
maintenance culture, ES cells embark on continuous progression to lineage commitment. The initial phase is reversible until the
ground state factors are entirely dissipated (shown by representative factors in light blue). Cells then reach a transitional point
characterized by the absence of either naı̈ve factors or lineage markers and the continued presence of Oct4 and Sox2. Cells in this
transitional phase are competent for lineage specification: They upregulate lineage markers in response to external signals (FGF,
Nodal, Wnt) and become primed for lineage commitment. Primed pluripotent cells finally leave the pluripotent state and enter
definitive lineages. Neuroectodermal (Sox2 and Brn2 positive) and mesendodermal (Oct4 and Sox17 positive) progenitors are depicted.
ES cells transition into lineage commitment without the requirement for an exogenous inducer,
although it should be noted they express FGF4 and upregulate Nodal. Loss of ES cell character is
not an instantaneous event, however. For !24 h, all cells remain able to self-renew as efficiently
as at time zero in a colony forming assay if restored to 2i+LIF, even though there is substantial
downregulation of ground state factors during this time. Extending the withdrawal period over
the 24–72-h period progressively reduces ability to regain self-renewal (Betschinger et al. 2013).
Thus, the initial phase of exit from the ground state is reversible until cells reach a transition point
at which ES cell identity is permanently extinguished (Kalkan & Smith 2014) (Figure 2).
Cells reach the transition point at different times after 2i withdrawal, however. This asynchrony
can be a confounding factor for time course analyses at the population level. It is not eliminated
by cell cycle synchronization of starting populations and therefore calls for fractionation based on
markers of developmental state, such as Rex1:GFPd2 (Kalkan & Smith 2014), time-lapse studies,
and/or single-cell profiling.
Fluctuatin pluripotency factor expression has not been do umented after 2i withdrawal in
serum-free culture. Comprehensive time-lapse imaging of fluorescent reporters has yet to be
described, and therefore a period of metastability is not formally excluded. However, delineation
of a reversible phase at the initiation of differentiation provides another possible explanation for
dynamic heterogeneity observed in LIF and serum. In serum, cells may enter and persist in the
reversible phase then sporadically revert owing to the presence of LIF.
LIF signaling plays a key role in reversibility; cells late in the reversible phase respond poorly
to 2i alone, whereas 2i+LIF has the capacity to fully restore ground state self-renewal. This may
parallel the role of LIF signaling in reprogramming, where it is required not simply to promote
self-renewal of emergent iPS cells but also for induction of the naı̈ve pluripotent state (Yang et al.
2010). The LIF/Stat3 targets Tfcp2l1 and Klf4 are plausible mediators in this context because
both have potent reversion activities (Guo et al. 2009, Martello et al. 2013, Ye et al. 2013).
Acute susceptibility to the environment suggests that the naive pluripotency network may be
poised to collapse. Does the network dissolve passively, or is it actively dismantled?
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that the naïve pluripotent cell is globally demethylated compared to the primed 
pluripotent cell. The open chromatin landscape of the naïve cell compared to the 
primed cell confers two advantageous properties for in vitro stem cell biology: 
more potent differentiation capabilities and enhanced gene targeting via plasmid-
based homologous recombination. Modified from Barth and Imhof (2010)106. 
 
(B) The stages of stem cell potency described in (A) are depicted here with a focus on 
the key transcription factor circuits involved in maintaining a particular cell fate. 
The progression from ground state naïve pluripotency to lineage commitment 
involves a gradual loss in naïve factors (light blue). The first transition is initially 
reversible until naïve factors (Tfcp2l1, Esrrb, Nanog) are gradually lost in the 
transitional state. In response to external signals (such as FGF, Nodal, and Wnt), 
cells in the transitional stage upregulate lineage markers (such as Sox17, Brn2, 
and T) on their way to primed pluripotency. Primed pluripotent cells are then free 
to enter definitive lineages. Shown here are neuroectodermal (Sox2 and Brn2 
positive) and mesendodermal (Oct4 and Sox17 positive) progenitors. Used 
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Initial morphological characterization 
in NHSM have domed-shaped colonies resembling murine naive cells;
thus we refer to the selected cells as naive human pluripotent stem cells
(hPSCs; includes human iPS cells and human ES cells), as we system-
atically validate the evidence for this claim.
We examined whether NHSM conditions allow derivation of new
human ES cell lines from human blastocysts. Human-blastocyst-derived
inner cell masses were plated in NHSM conditions, and successfully
generated domed cell outgrowths after 6–8 days (Fig. 1d). We were able
to establish four newly derived naive human ES cell lines termed LIS1,
LIS2, WIS1 and WIS2 (Fig. 1d and Extended Data Fig. 1g). Several
conventional (hereafter will be named ‘primed’) already established
human ES cell lines (H1, H9, BGO1, WIBR1, WIBR2 and WIBR3) and
human iPS cell lines (C1 and C2) were plated on gelatin/vitronectin-
coated dishes in NHSM medium. After 4–8 days, dome-shaped col-
onies with packed round cell morphology could be readily isolated and
further expanded (Fig. 1e). Human fibroblast cells were reprogrammed
to human iPS cells in NHSM following reprogramming factor trans-
duction (data not shown). All human ES cell and iPS cell lines expanded
in NHSM conditions were positive for pluripotent markers and formed
mature teratomas in vivo (Extended Data Fig. 2). Human naive plur-
ipotent lines maintained normal karyotype after extended passaging
following trypsinization and expansion on irradiated mouse embry-
onic fibroblast (MEF) feeder cells or on vitronectin/gelatin-coated
plates (Extended Data Fig. 2a). The average doubling time was signifi-
cantly reduced from 26 h for primed hPSCs down to 14 h for naive
hPSCs (Extended Data Fig. 3a). Naive hPSCs displayed up to 35%
single-cell cloning efficiency after trypsinization and sorting (without
the use of ROCK inhibitors), whereas primed hPSCs largely did not
survive single-cell cloning (Extended Data Fig. 3b). In the presence of
ROCK inhibitor, naive hPSCs had single-cell cloning efficiency of up to
88%, whereas that of primed cells increased only up to 22% (Extended
Data Fig. 3b, c).
We next aimed to characterize epigenetic features in naive human
iPS cells and human ES cells established in NHSM conditions. Primed
and naive human ES cell/human iPS cells were transfected with a luci-
ferase reporter construct under the control of either the human distal
(DE) or the proximal (PE) enhancer sequences that control expression
of the OCT4 gene (also known as POU5F1). Consistent with previous
reports, primed human ES cells showed preferential activation of
the proximal OCT4 enhancer element as typically seen in murine
EpiSCs6,7. Remarkably, predominant utilization of the OCT4 distal
enhancer was detected in naive human ES cells and human iPS cells
(Extended Data Fig. 3d). To further substantiate these findings, WIBR3
human ES cells were stably transfected with full-length OCT4–GFP–
2A–PURO, DPE–OCT4–GFP–2A–PURO or DDE–OCT4–GFP–2A–
PURO engineered BAC reporter constructs (Extended Data Fig. 3e).
The wild-type OCT4–GFP reporter was specifically active in both
naive and primed conditions (Fig. 2a). The DPE–OCT4–GFP reporter
was predominantly active in naive growth conditions whereas the
DDE–OCT4–GFP reporter was more active in primed pluripotent cells
(Fig. 2a). We then analysed the frequency and properties of X inac-
tivation state12 in several naive human ES cell/human iPS cell lines.
Naive hPSCs captured in NHSM maintain a pre-X inactivation state
as evident by nearly complete lack of H3K27me3 nuclear foci and
down regulation of XIST transcription. The majority of primed hPSCs
demonstrated X inactivation as evident by the presence of H3K27me3
nuclear foci and methylation of one of the XIST gene alleles (Fig. 2b and
Extended Data Fig. 4a–d)13. Genome-wide mapping of H3K9me3 by
chromatin immunoprecipitation, followed by deep sequencing (ChIP-
seq) in female and male naive and primed human pluripotent cells,
indicated a significant increase (P , 3.8 3 10–63) in this mark on the X
chromosome only in female primed pluripotent cells (Extended Data
Fig. 4c). XIST promoter alleles are demethylated in male and female
naive ES cells (Extended Data Fig. 4d). Upon differentiation of female
naive human ES cells/human iPS cells, inactivation of one of the X
chromosomes alleles becomes evident as the cells demonstrate H3K27me3
clouds, upregulate XIST transcription simultaneously with methyla-
tion of one of the promoters of XIST alleles (Fig. 2b and Extended Data
Fig. 4a–d).
Next we compared global gene expression patterns between naive
and primed human ES cells and human iPS cells. Unbiased clustering
of genome-wide expression profiles demonstrated that naive human
a 
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Figure 1 | Capturing the ground state of human
naive pluripotency. a, Schematic drawing of the
strategy used for calibrating conditions to isolate
naive transgene-independent human iPS cells
(hiPSCs) in the presence of 2i/LIF. Inhibitor is
abbreviated as ‘i’ in the dotted box. Scale bar,
200mm. b, Components of optimized NHSM
conditions. c, Representative large-field view of
OCT4–GFP1 human iPS cell colonies grown in
NHSM (left) and, for comparison, primed/
conventional iPS cells (right). Scale bars, left,
200mm; right, 50mm. d, Human-blastocyst-
derived inner cell masses were plated on feeder cells
in NHSM conditions. At day 6–8, the original
outgrowth was trypsinized, and naive pluripotent
cell lines were established in NHSM conditions
(representative images of established line at the
indicated passage (P) are shown). hESC, human
embryonic stem cell. Scale bars, left, 50mm; right,
200mm. e, Epigenetic reversion of already
established primed/conventional human ES cells to
naive ground state. Representative images of BGO1
human ES cell line are shown. Scale bars, left,
200mm; right, 30mm.
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human iPS cell lines (C1 and C2) were plated on gelatin/vitronectin-
coated dishes in NHSM medium. After 4–8 days, ome-shaped col-
onies with packed round cell morphology could be readily isolated and
further expanded (Fig. 1e). Human fibroblast cells were re rogrammed
to human iPS cells in NHSM following reprogram ing factor tra s-
duction (data not shown). All human ES cell and iPS cell lines expanded
in NHSM conditions were positive for pluripote t markers a formed
mature teratomas in vivo (Extended Data Fig. 2). Human naive plur-
ipotent lines maintained normal karyotype after extended passaging
following trypsinization and expansion on irradiated mouse embry-
onic fibroblast (MEF) feeder cells or on vitronect n/gel tin-coated
plates (Extended Data Fig. 2a). The average doubling tim was signifi-
cantly reduced from 26 h for primed hPSCs down to 14 h for naive
hPSCs (Extended Data Fig. 3a). Naive hPSCs displayed up to 35%
single-cell cloning efficiency after trypsinization and sorting (without
the use of ROCK inhibitors), whereas primed PSCs largely did not
survive single-cell cloning (Extended Data Fig. 3b). In the presen e of
ROCK inhibitor, naive hPSCs had single-cell cloning efficiency of up to
88%, whereas that of primed cells increased only up to 22% (Extended
Data Fig. 3b, c).
We next aimed to characterize epigenetic features in naive human
iPS cells and human ES cells established in NHSM onditions. Primed
and naive human ES cell/human iPS cells were transfected with a luci-
ferase reporter construct under the control of either the human distal
(DE) r the p oxi a (PE) enhancer s quences that c ntrol expression
of the OCT4 gene ( lso known as POU5F1). C nsistent with pr vious
report , primed human ES cells showed preferential activation of
the proximal OCT4 enhancer element as typically seen in murine
Epi Cs6,7. Remarkab y, pr dom nant utilization of the OCT4 distal
enhancer was detected in naive human ES cells and hum n iPS ells
(Exte ded Data Fig. 3d). To further substantiate these fin ings, WIBR3
human ES cells were stably transfected with full-length OCT4–GFP–
2A–PURO, DPE–OCT4–GFP–2A–PURO or DDE–OCT4–GFP–2A–
PURO engine re BAC reporter constructs (Extended Data Fig. 3e).
The wild-type OCT4–GFP repor er was specifically activ in both
naive and primed conditions (Fig. 2a). The DPE–OCT4–GFP reporter
was predominantly active in naive growth conditions whereas the
DDE–OCT4–GFP reporter was more active in primed pluripotent c lls
(Fig. 2a). We then analyse the frequency and properties of X inac-
tivatio state12 in s veral naive human ES cell/human iPS cell lines.
Naive hPSCs ca tured in NHSM maintain a pre-X inactivation state
as evide t by ne rly comp ete lack of H3K27m 3 nuclear foci and
d wn regulation of XIST transcription. The maj rity of primed hPSCs
demonstrated X inactivation s evident by the presence of H3K27me3
nuclear foci and methylation of one of the XIST gene lleles (Fig. 2b and
Ext nded Data Fig. 4a–d)13. Genome-wide mapping of H3K9me3 by
chromatin immunoprecipitation, followed by deep sequencing (ChIP-
seq in female an male naive and primed human pluripotent cells,
indicated a significant increase (P , 3.8 3 10–63) in this mark on the X
chromosom only in female primed pluripotent cells (Extended Data
Fig. 4c). XIST promoter alleles are demethylated in male and fe al
naive ES cells (Ext nded Data Fig. 4 ). Upon differ ntiation of femal
naiv human ES cells/human iPS c lls, inactiv tion of one of the X
chromo omes alle es becomes evident as the cells demonstrate H3K27m 3
clouds, up gulate XIST ranscription simultaneou ly with methyla-
tion of one of the promoters of XIST alleles (Fig. 2b and Extend d Data
Fig. 4a–d).
Next we compared global gene expression patterns b tween naive
and pr med human ES cells an hum n iPS cells. Unbiased clustering
of genome-wide expression profiles demonstrated that naive human
a 
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Figure 1 | Capturing the ground state of human
naive pluripotency. a, Schematic drawing of the
strategy used for calibrating conditions to isolate
naive transgene-independent human iPS cells
(hiPSCs) in the presence of 2i/LIF. Inhibit r is
abbreviated as ‘i’ in the dotted box. Scale bar,
200mm. b, Components of optimized NHSM
condi ions. c, Representative large-field view of
OCT4–GFP1 human iPS cell colonies grown in
NHSM (left) and, for comparison, primed/
conventional iPS cells (right). Scale bars, left,
200mm; right, 50mm. d, Human-blastocyst-
derived inner cell masses were plated on feeder cells
in NHSM conditions. At day 6–8, the original
outgrowth was trypsinized, and naive pluripotent
cell lines were established in NHSM conditions
(representative images of established line at the
indicated passage (P) are shown). hESC, human
embryonic stem cell. Scale bars, left, 50mm; right,
200mm. e, Epigenetic reversion of already
established primed/conventional human ES cells to
naive ground state. Representative images of BGO1
human ES cell line are shown. Scale bars, left,
200mm; right, 30mm.
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Figure 3: Naïve pluripotency revises the clinical iPS paradigm 
 
(A) The clinical paradigm of iPS reprogramming technology. Here, patient-specific 
iPS cells generated from skin biopsy cells via ectopic co-expression of the 
Given the number f drugs that have notoriously been withdrawn from 
the market because of their tendency to induce arrhythmias, it is highly 
likely that the current inadequate approaches for assessing cardiotoxic-
ity will be complemented by iPS-cell-based assessments of drug effects.
A study from our laboratory explored dyskeratosis congenita, a dis-
order of telomere maintenance, and provided an unanticipated insight 
into the basic biology of telomerase that has therapeutic implications73. 
In its most severe form, dyskeratosis congenita is caused by a mutation 
in the dyskerin gene (DKC1), which is X linked, leading to shortened tel-
omeres and premature senescence in cells and ultimately manifesting as 
the degeneration of multiple tissues. Because the reprogramming of cells 
to an induced pluripotent state is accompanied by the induction of the 
gene encoding telomerase reverse transcriptase (TERT), we investigated 
whether the telomerase defect would limit the derivation and mainte-
nance of iPS cells from individuals with dyskeratosis congenita. Although 
the efficiency of iPS-cell derivation was poor, we were able to successfully 
reprogram patient fibroblasts. Surprisingly, whereas the mean telomere 
length immediately after reprogramming was shorter than that of the 
parental fibroblast population, continued passage of some iPS cell lines 
led to telomere elongation over time. This process was accompanied by 
upregulation of the expression of TERC, which encodes the RNA subunit 
of telomerase.
Further analysis established that TERT and TERC, as well as DKC1, 
were expressed at higher levels in dyskeratosis-congenita-derived iPS cells 
than in the parental fibroblasts73. We determined that the genes encoding 
these components of the telomerase pathway — including a cis element 
in the 3ʹ region of the TERC locus that is essential for a transcriptionally 
active chromatin structure — were direct binding targets of the pluri-
potency-associated transcription factors. Further analysis indicated that 
transcriptional silencing owing to a 3ʹ deletion in the TERC locus leads to 
the autosomal dominant form of dyskeratosis congenita by diminishing 
TERC transcription. Although telomere length is restored in dyskeratosis-
co genita-derived iPS cells, differentiation into somatic cells is accompa-
nied by a return to pathogenesis with low TERC expression and a decay in 
telomere length. This finding showed that TERC RNA levels are dy ami-
cally regulated and that the pluripotent state of the cells is reversible, sug-
gest g that drug  that elev te or stabilize T RC expression might rescue 
defective telomerase activity and provide a therapeutic benefit. Although 
we set out to understan  the pathogenesis f dyskeratosis conge ita with 
this study, we showed that a high expression level of multiple telomera e 
components was characteristic of the pluripotent state more generally, 
illustrating how iPS cells can reveal fundamental aspects of cell biology.
An independent study of the reprogramming of cells from patients with 
dyskeratosis congenita confirmed the general transcriptional upregula-
tion of multiple telomerase components and the maintenance of telomere 
lengths in clones74; however, in this study, no clones with elongated telom-
eres were identified. The different outcomes of these studies highlight the 
limitations of iPS-cell-based disease models that are imposed by clonal 
variation as a result of the inherent technical infidelity of reprogram-
ming75. This point also introduces an additional important consideration. 
Before a given iPS-cell disease model can be claimed to be truly represent-
ative of the disease, how many patients must be involved, and how many 
iPS cell lines must be derived from each patient? Although the answers to 
these questions are unclear, it is crucial to keep these issues in mind when 
generating disease models and making claims based on these models.
Although iPS cells are an invaluable tool for modelling diseases in vitro, 
the goal of developing patient-specific stem cells has also been motivated 
by the prospect of generating  eady supply of immune-compati le cells 
and tissues for autologous transplantation. At present, the clinical trans-
lation of iPS-cell-based cell therapies seems more futuristic than the in 
vitro use of iPS cells for research and drug development, but two ground-
breaking studies have provided the proof of principle in mouse models 
that the dream might one day be realized. Hanna, Jaenisch and colleagues 
used homologous recombination to repair the genetic defect in iPS cells 
derived from a humanized mouse model of sickle-cell anaemia76. Directed 
differentiation of the repaired iPS cells into haematopoietic progenitors 
followed by transplantation of these cells into the affected mice led to 
the rescue of the disease phenotype. The gene-corrected iPS-cell-derived 
haematopoietic progenitors showed stable engraftment and correction of 
the disease phenotype.
In another landmark study from Jaenisch’s research group, Wernig 
and colleagues derived dopaminergic neurons from iPS cells that, when 
implanted into the brain, became functionally integrated and improved 
the condition of a rat model of Parkinson’s disease77. The successful 
implantation and functional recovery in this model is evidence of the 
therapeutic value of pluripotent stem cells for cell-replacement therapy 
in the brain — one of the most promising areas for the future of iPS-
cell applications.
Figure 2 | Medical applications of iPS cells. 
Reprogramming technology and iPS cells have 
the potential to be used to model and treat 
human disease. In this example, the patient has 
a neurodegenerative disorder. Patient-specific 
iPS cells — in this case derived by ectopic 
co-expression of transcription factors in cells 
isolated from a skin biopsy — can be used in one 
of two pathways. In cases in which the disease-
causing mutation is known (for example, familial 
Parkinson’s disease), gene targeting could be 
used to repair the DNA sequence (right). The 
gene-corrected patient-specific iPS cells would 
then undergo directed differentiation into the 
affected neuronal subtype (for example, midbrain 
dopaminergic neurons) and be transplanted into 
the patient’s brain (to engraft the nigrostriatal 
axis). Alternatively, directed differentiation of 
the patient-specific iPS cells into the affected 
neuronal subtype (left) will allow the patient’s 
disease to be modelled in vitro, and potential drugs 
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Yamanaka factors (OCT4, SOX2, KLF4, and c-MYC) can be used for in vitro 
differentiation and personalized drug screening (left path); or can be used to 
correct an inherited mutational disorder in vitro via powerful genome editing 
technologies and subsequently re-differentiated into desired lineages for 
transplantation therapy (right path). The benefit of using iPS cells here is that 
these cells are always genetically matched to a specific patient (the patient 
provides the somatic cells prior to reprogramming). Used unmodified from 
Robinton and Daley (2012)108. 
 
(B) Naïve pluripotency reshapes the canonical iPS cell paradigm presented in (A). As 
Zimmerlin et al. (2015) argue, by combining the utility of high fidelity optimized 
reprogramming to pluripotency together with naïve reversion, we may create new 
opportunities for gene repair and in vitro directed differentiation to operate with 
clinically relevant efficiencies and kinetics. Note that the path begins with a 
graphic depicting stromal-primed reprogramming of myeloid progenitors109. 
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designed to bind on opposite sides of the target site with the
respective FokI domains oriented toward each other (Fig. 1).
This design further enhances the specificity of ZFNs, as
dimerization of FokI and thus cleavage are dependent on a lon-
ger target. A pair of ZFNs that each contains three zinc finger
motifs are sufficient to ensure a unique intended target of an
18-bp sequence by chance in the human genome, although four
to six motifs are more commonly used to increase specificity
(12). ZFNs have been successfully used to edit the genome of
many organisms, including humans (11, 13).
Among the synthetic nucleases, ZFNs have the advantage of
being the most studied. There are many technical resources to
aid the design and assembly of ZFNs. Well designed ZFNs are
highly effective in the disruption, addition, or correction of the
target gene. Recently, ZFN-mediated disruption of the TAP2
gene in hiPSCs made it possible to produce an unlimited
amount of antigen-presenting cells for vaccination therapy
(14). ZFN-mediated insertion of transgenes into the genomic
safe harbor locus (AAVS1) of hiPSCs has been used to engineer
cells for in vivo imaging and to correct the globin imbalance in
!-thalassemia (15, 16). In the case of HDR, ZFNs greatly sim-
plify the experimental design, as short oligonucleotides may be
used as templates, and antibiotic selection may be omitted (17).
For a detailed account of genome editing of hESCs and hiPSCs
using ZFNs, we would like to refer the readers to recent reviews
(18, 19).
Despite many successful reports of ZFN-mediated genome
editing of human cells in academic and clinical research, ZFN
technology has several limitations. The assembly of zinc finger
motifs is not modular in the strictest sense. The binding affinity
of individual motifs is context-dependent. In other words, an
assembled ZFN does not necessarily have high affinity for the
sequence that is the composite of the 3-bp cognate sequence of
each zinc finger motif (20). Other selection-based methods
have been invented to address the high failure rate of modularly
assembled ZFNs (reviewed in Ref. 14). With these methods, the
number of targetable sites is reduced. In any case, it requires a
considerable amount of experience, time, and effort to achieve
proficiency at making functional ZFNs.
Unintended cleavage at so-called off-target sites is another
concern with ZFNs (21). Off-target cleavage could cause cyto-
toxicity, introduce unknown mutations, and confound the
analysis of the effects of the intended genetic changes. FokI
variants that form obligate heterodimers have been used to
minimize off-target cutting due to homodimerization of ZFNs
(22). Converting FokI into a DNA-nicking enzyme also helps to
FIGURE 1. Conceptual schematic showing the application of genome editing and iPSC technologies in regenerative medicine.
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Figure 4: Genome editing technologies and the ground state advantage 
(A) The curr nt genome edit ng toolbox. Five technologies exist to gene target 
pluripotent stem cells. Of the five, two are nuclease-free: (1) helper-dependent 
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direct plasmid-based homologous recombination. The remaining three are 
nuclease-assisted and derived primarily to overcome the weak homologous 
recombination capacity of primed pluripotent stem cells. These technologies 
simply create synthetic double-strand breaks (DSBs) in DNA and require the co-
transfection of donor sequences to mediate sequence-specific edits via 
endogenous HR. These include: (1) zinc-finger nucleases (ZFNs); (2) 
transcription activator-like effector nucleases (TALENs); and (3) clustered 
regularly interspaced short palindromic repeat - associated nuclease 9 (CRISPR-
Cas9) technology. Modified from Li et al. (2014)49. 
 
(B) Of the technologies presented in (A), the nuclease-free technologies make 
sequence-specific edits in the genome via two endogenous, and competing, DSB-
repair pathways: homologous recombination (HR) and non-homologous end 
joining (NHEJ). Shown here are targeting vectors with two homology arms and 
neomycin drug-resistance being integrated into the genome in a sequence-
specific manner via HR (targeted integration) or randomly via NHEJ (random 
integration). Primed cells have greater capacity for NHEJ and therefore require 
the assistance of synthetic DSBs to mediate correct sequence-specific targeting. 
Modified from Nobelprize.org110. 
 
(C) When synthetic-nucleases are used to mediate gene targeting, DSBs in DNA can 
lead to sequence-specific insertions or corrections (red box) via homology-
directed repair (HDR) in the presence of a double-stranded donor template or 
single-stranded oligodeoxynucleotide (ssODN), each of which contain homology 
arms. The induced DSBs can also be repaired via error-prone NHEJ, which does 
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not require any template sequence and therefore can lead to mutational insertions 
and deletions (indels). Modified from Kim and Kim (2014)111. 
 
(D) Primed pluripotent cells are globally hypermethylated relative to naïve cells and 
therefore possess a tighter chromatin landscape. Additionally, endogenous 
enzymatic machinery in the primed background favors error-prone NHEJ (which 
mediates random integration of plasmid-based gene targeting vectors). 
 
(E) Naïve pluripotent cells are globally hypomethylated relative to naïve cells and 
therefore possess a more open chromatin landscape. Endogenous enzymatic 
machinery in the naive background favors HR (which mediates targeted 



















Figure 5: NHEJ and the indirect depletion of DNA-PKCS by XAV939 
 
(A) Under normoxia, DNA DSBs are sensed by the MRE11–RAD50–NBS1 
complex, leading to recruitment and activation of DNA-dependent protein kinase 
(DNA-PK) catalytic subunit (DNA-PKCS) and ataxia telangiectasia mutated 
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the DSB. Subsequently, a number of DNA damage-sensing proteins such as p53-
binding protein 1 (53BP1) and mediator of DNA damage checkpoint 1 (MDC1) 
are recruited for use in HR and NHEJ. HR molecules are indicated in light green 
and NHEJ molecules are indicated in blue. Red arrows indicate DNA-PKCS 
molecules. Modified from Bristow and Hill (2008)52. 
 
(B) As part of the initial phases of NHEJ, a Ku70/80 heterodimer, together with 
DNA-PKCS, associate at the site of a DSB to protect against premature ligation 
and degradation of DNA termini. Trans auto-phosphorylation of DNA-PKCS 
induces a conformational change in the DNA-PKCS/Ku70/80 complex to make 
DNA termini more accessible for other NHEJ ligases and processing enzymes. 
ATM-mediated DNA-PKCS phosphorylation (together with trans auto-
phosphorylation) may play a role in this conformational change. Modified from 
Weterings and Chen (2008)53. 
 
(C) XAV939 is shown to target TNKS1, which relies on poly(ADP-ribose) 
glycohydrolase (PARG) activity to remove an auto-poly(ADP-ribose) group 
(auto-pADPr) to remain in an active state (green); otherwise, the enzyme is 
ubiquitinated in an inactive state (red) and targeted for proteasome-mediated 
degradation. In an active state, TNKS1 PARsylates unmodified DNA-PKCS 
(green arrow). This modification can be reversed via PARG activity (light blue 
arrow). After TNKS1 has PARsylated DNA-PKCS, it is auto-PARsylated 
(inactive red) and targeted for proteasome-mediated degradation. PARsylated 
DNA-PKCS are active and free to act in NHEJ repair of DNA DSBs; however, 
if DNA-PKCS is not PARsylated by TNKS1, it is marked for subsequent 
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proteasome-mediated degradation (right of schematic). If the PARP catalytic 
activity of TNKS1 is depleted or inhibited (here by XAV939), DNA-PKCS 
accumulates in its unmodified form and is forced towards proteasome-mediated 
depletion. Note that translation of DNA-PKCS mRNA renews the unmodified 
DNA-PKCS population, while translation of TNKS1 mRNA renews the active 














































Figure 6: Naïve pluripotency provides a future platform for the interspecies 
generation of human organs in livestock animals 
 
(A) The use of naïve patient-specific iPSC in blastocyst complementation with 
organogenesis-disabled livestock. Modified from Rashid et al. (2014)62. 
 
(B) The use of naïve patient-specific iPSC in conceptus complementation in utero 
with organogenesis-disabled livestock. Modified from Rashid et al. (2014)62. 
PSC-derived cells and then ‘‘comple-
menting’’ this deficiency to generate
a newly formed pancreas composed
entirely of injected cells (though vessels,
nerves, and interstitial cells were
composed of both host and donor cells;
Kobayashi et al., 2010). These comple-
mented embryos survived to adulthood
without abnormalities, indicating that the
PSC-derived pancreas was functional.
We have obtained similar success in
PSC-derived organ generation for kidney
(Usui et al., 2012). Thus, the concepts of
‘‘organ niche’’ and ‘‘developmental
compensation’’ have been repeatedly
validated experimentally both by us and
others (Isotani et al., 2011, Matsunari
et al., 2013, Kobayashi et al., 2014).
From Rodents to Large Animals
In order to directly translate these experi-
mental observations into the clinical goal
of making patient-specific transplantable
organs, embryos lacking the ability to
generate various organs would be
requir d. Following organ procurement,
however, those embryos would be sacri-
ficed. Clearly from an ethical and social
perspective this strategy is not appro-
priate to apply to human embryos.
However, given the anatomical and phys-
iological similarity that exists between
human and livestock animal organs, we
might alternatively think about deriving
such organ-generating resources from
pigs an heep. P gs are particularly
good animals to use for this purpose
because developmental/genetic engi-
neering techniques like somatic cell nu-
clear transfer (SCNT) are readily available.
Figure 1A outlines this approach. If it
works, although produced in the body of
a pig, the organs would consist of cells
derived from the patient’s own iPSCs,
making the subsequent transplantation
essentially autologous.
While apparently simple, there are a
few significant technical challenges that
need to be addressed before this principle
of organ generation in large animals can
be applied further. These challenges
include issues related to interspecies
chimera generation, large-scale produc-
tion of organ-deficient embryos, the
developmental potential of human PSCs,
posttransplantation cell homing, immune
rejection, and safety and ethical issues.
To address the first issue, we started by
trying to break the interspecies boundary
through transplanting rat iPSCs into
the blastocysts of pancreatogenesis-
disabled mice and vice-versa. As hoped,
we were able to obtain chimeric animals,
giving proof, in rodents at least, that inter-
species complementation was possible.
Interestingly, and as an unexpected sec-
ondary observation, chimeric animals
were found to be either mouse-sized or
rat-sized depending on the host blasto-
cyst—indicating that organ size was
determined by the environment and not
by the donor cells. Shortly after our own
rep rt, a secondgroupconfirmed theprin-
ciple of interspecies complementation
through blastocyst injection using rat
ESCs injected into a mouse embryo engi-
neered to lack a thymus (nu/nu). The
chimeric animals’ thymuses were found
to have been derived from the donor rat
cells, therefore confirming that the pro-
cess could be extended to generate
different organs (Isotani et al., 2011). The
second issue of breeding suitable
numbers of host recipients was ad-
dressed by extending our previousmouse
study inwhichwedemonstrated thatHes1
acts as a fate determinant switch between
the biliary and pancreatic system (Suma-
zaki et al., 2004). Based on these data,
we made transgenic mice with Pdx1-
Hes1 constructs to overexpress Hes1 in
every Pdx1-expressing cell. Transgenic
embryos showed an apancreatic pheno-
type as expected. We then generated a
transgenic pig using the same construct
and succeeded in obtaining apancreatic
embryos just as we had observed in the
mouse. We collected large numbers of fi-
broblasts from this porcine embryo and
carried out SCNT using these fibroblasts
as donor nuclei. The cloned embryos ob-
tained had the same apancreatic pheno-
type, indicating that apancreatic embryos
can be obtained as long as we perform
SCNT using these fibroblasts. As in the ro-
dent system, apancreatic pigs survived to
adulthoodwhen theywere complemented
at the blastocyst stage. Some of them
grew to maturity and became fertile. The
complemented apancreatic male pigs
produced sperm that could also be used

















Figure 1. Potential Methodologies for the Interspecies Generation of Human Organs
(A) Generation of human organs using blastocyst complementation of organogenesis-disabled livestock.
(B) Generation of human organs using in utero conceptus complementation of organogenesis-disabled livestock.
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PSC-derived cells and then ‘‘comple-
menting’’ this deficiency to generate
a newly formed pancreas composed
entirely of injected cells (though vessels,
nerves, and interstitial cells were
composed of both host and donor cells;
Kobayashi et al., 2010). These comple-
mented embryos survived to adulthood
without abnormalities, indicating that the
PSC-derived pancreas was functional.
We have obtained similar success in
PSC-derived organ generation for kidney
(Usui et al., 2012). Thus, the concepts of
‘‘organ niche’’ and ‘‘developmental
compensation’’ have been repeatedly
validated experimentally both by us and
others (Isotani et al., 2011, Matsunari
et al., 2013, Kobayashi et al., 2014).
From Rodents to Large Animals
In order to directly translate these experi-
mental observations into the clinical goal
of making patient-specific transplantable
organs, embryos lacking the ability to
generate various organs would be
required. Following organ procurement,
however, those embryos would be sacri-
ficed. Clearly from an ethical and social
perspective this strategy is not appro-
priate to apply to human embryos.
However, given the anatomical and phys-
iological similarity that exists between
human and livestock animal organs, we
might alternatively think about deriving
such organ-generating resources from
pigs and sheep. Pigs are particularly
good animals to use for this purpose
because developmental/genetic engi-
neering techniques like somatic cell nu-
clear transfer (SCNT) are readily available.
Figure 1A outlines this approach. If it
works, although produced in the body of
a pig, the organs would consist of cells
derived from the patient’s own iPSCs,
making the subsequent transplantation
essentially autologous.
While apparently simple, there are a
few significant technical challenges that
need to be addressed before this principle
of organ generation in large animals can
be applied furth r. These challenges
include issues related to interspecies
chimera generation, large-scale produc-
tion of organ-deficient embryos, the
developmental potential of human PSCs,
posttransplantation cell homing, immune
rejection, and safety and ethical issues.
To address the first issue, we started by
trying to break the interspecies boundary
through transplanting rat iPSCs into
the blastocysts of pancreatogenesis-
disabled mice and vice-versa. As hoped,
we were able to obtain chimeric animals,
giving proof, in rodents at least, that inter-
species complementation was possible.
Interestingly, and as an unexpected sec-
ondary observation, chimeric animals
were found to be either mouse-sized or
rat-sized depending on the host blasto-
cyst—indicating that organ size was
determined by the environment and not
by the donor cells. Shortly after our own
report, a secondgroupconfirmed theprin-
ciple of interspecies complementation
through blastocyst injection using rat
ESCs injected into a mouse embryo engi-
neered to lack a thymus (nu/nu). The
chimeric animals’ thymuses were found
to have been derived from the donor rat
cells, therefore confirming that the pro-
cess could be extended to generate
different organs (Isotani et al., 2011). The
second issue of bre ding suitable
numbers of host recipients was ad-
dressed by extending our previousmouse
study inwhichwedemonstrated thatHes1
acts as a fate determinant switch between
the b liary a d pancreatic system (Suma-
zaki et al., 2004). Based on these data,
we made transgenic mice with Pdx1-
Hes1 constructs to overexpress Hes1 in
every Pdx1-expressing cell. Transgenic
embryos showed an apancreatic pheno-
type as expected. We then generated a
transgenic pig using the same construct
and succeeded in obtaining apancreatic
embryos just as we had observed in the
mouse. We collected large numbers of fi-
broblasts from this porcine embryo and
carried out SCNT using these fibroblasts
as donor nuclei. The cloned embryos ob-
tained had the same apancreatic pheno-
type, indicating that apancreatic embryos
can be obtained as long as we perform
SCNT using these fibroblasts. As in the ro-
dent system, apancreatic pigs survived to
adulthoodwhen theywere complemented
at the blastocyst stage. Some of them
grew to maturity and became fertile. The
complemented apancreatic male pigs
produced sperm that could also be used

















Figure 1. Potential Methodologies for the Interspecies Generation of Human Organs
(A) Generation of human organs using blastocyst complementation of organogenesis-disabled livestock.
(B) Generation of human organs using in utero conceptus complementation of organogenesis-disabled livestock.
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Figure 7: Instability in primed bFGF/KOSR-dependent ORMES-22, CRES-2 
SCNT, and rPESC lines 
 
Primed ORMES-22, CRES-2 somatic cell nuclear transfer (SCNT), and 
parthenogenetic rhesus ESC (rPESC) lines show instability when grown with basic 
fibroblast growth factor (bFGF) under basal hESC medium supplemented with 20% 
knockout serum replacement (KOSR). Primed cultures were imaged using phase 




































Figure 8: Examination of naïve rhesus ESC domed-shaped morphology and 
clonal expansion post single cell passaging under different in vitro conditions  
 
(A) ORMES-22 p9 rhesus ESCs (rESCs) cultured in LIF 3i for 12 passages (left) and 
ORMES-22 p9 rESCs cultured in LIF 5i for 1 passage plus LIF 3i for 11 passages 
(right). Representative colonies are depicted. Phase contrast. Top panel, scale bar 
= 200 µm; bottom panel, scale bar = 100 µm. 
 
(B) ORMES-22 p9 + 1 LIF 5i + 10 LIF 3i cells were cultured for two additional 
passages in either LIF 3i, LIF 3i supplemented with 20 ng/mL bFGF, or LIF 3i 
supplemented with 10 ng/mL BMP4 (under both normoxic and hypoxic 
conditions). Cell viability is depicted as measured by trypan blue exclusion. A 2-
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way ANOVA was employed together with Sidak’s multiple comparisons test in 
GraphPad Prism to assess statistical significance. **** = P ≤ 0.0001; ** P ≤ 0.01. 
n = 3 wells per condition; mean ± SD indicated. 
 
(C) ORMES-22 p9 rESCs cultured in LIF 5i for 1 passage, and LIF 3i for 11 passages 
were subjected to six different culture conditions. Representative colonies are 
depicted after 9-day treatment. Top panel: normoxia; bottom panel: hypoxia. 
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Figure 9: Direct conversion of primed ORMES-22 p13 rESCs with one passage 
of LIF 5i and further passaging in LIF 3i or LIF 4i 
 
(A) Protocol timeline depicting the conversion of primed pluripotent stem cells to 
poly-clonal naïve-like pluripotent stem cells. Conversion consists of three phases: 
regular bFGF primed culture, adaptation to naïve medium for 48 hours, and poly- 
clonal growth in naïve medium. 
 
(B) ORMES-22 p13 rESCs were converted with one passage of LIF 5i + 10 ng/mL 
bFGF (n = 3). Cells were then passaged into either LIF 3i or LIF 4i (consisting of 
LIF 3i + 1 µM sunitinib). All cultures were incubated under hypoxic conditions. 
Phase contrast. Scale bar = 500 µm. 
 
(C) ORMES-22 p13 + 1 LIF 5i rESCs were passaged into four different conditions: 
LIF 3i, LIF 3i + 1 µM sunitinib, LIF 3i + 10 mM LiCl, and LIF 3i + 1 µM 
sunitinib + 10 mM LiCl. Cell viability as measured by trypan blue exclusion was 
measured after one passage. An ordinary one-way ANOVA with Tukey’s 
multiple comparisons test was employed in GraphPad Prism to assess statistical 
significance versus the L3i control. **** =P ≤ 0.0001; *** = P ≤ 0.001; ** P ≤ 
0.01. n = 3 wells per condition; mean ± SD indicated. 
 
(D) ORMES-22 p13 + 1 LIF 5i cells were cultured for two additional passages in LIF 
3i or LIF 4i under hypoxic conditions. Shown is the fold change in live cells per 
passage. A 2-way ANOVA was employed together with Tukey’s multiple 
comparisons test in GraphPad Prism to assess statistical significance. ** P ≤ 0.01. 
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(E) ORMES-22 p13 + 1 LIF 5i + 3 LIF 3i or 4i rESCs were stained with BCIP/NBT 
substrate for alkaline phosphatase expression. H9 human embryonic stem cells 
(hESCs) at passage 55 were used as a positive control. Scale bar (wells) = 1500 
µm and scale bar (phase contrast microscopy) = 500 µm. 
 
(F) (i) Flow cytometry was conducted on ORMES-22 p13 + 1 LIF 5i cells to detect 
pluripotency surface markers using TRA-1-81 PE-conjugated and SSEA-4 APC- 
conjugated antibodies (n = 1). Top panel = TRA-1-81 stained cells with positive 
quadrant indicated; middle panel = SSEA-4 stained cells with positive quadrant 
indicated; bottom panel = doubly stained cells with positive quadrant indicated. 
APC = allophycocyanin; PE = phycoerythrin; SSC-H = side scatter (granularity); 
FSC-H = forward scatter (size); FL2-H = PE channel; FL4-H = APC channel. 
The left column depicts the SSC-H x FSC-H plots of all 10, 000 events recorded 
per staining; the right column depicts viable cells that were manually gated from 
each left column plot per staining. All analysis was conducted using FlowJo 
software. (ii) ORMES-22 p13 + 1 LIF 5i + 2 LIF 3i rESCs stained for SSEA-4 (n 
= 2; representative data indicated). (iii) ORMES-22 p13 + 1 LIF 5i + 2 LIF 4i 
rESCs stained for SSEA-4 (n = 2; representative data indicated). 
 
(G) Quantification from (E). A 2-way ANOVA with Sidak’s multiple comparisons 
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Figure 10: Direct conversion of ORMES-22 rESCs with varied combinations of 
LIF, CHIR, PD, and SU  
 
(A) ORMES-22 p19 rESCs were converted in the indicated conditions. Percentage 
recovery of live cells as measured by trypan blue exclusion was determined 9 
days post single-cell dissociation. 
 
(B) Comparative examination of dome shaped morphology across the 12 different in 
vitro culture conditions indicated in (A) after one passage. Cells were imaged 
under phase contrast. Scale bar = 500 µm. 
 
(C) Examination of morphology after two passages in the indicated conditions. Phase 
contrast; scale bar = 500 µm. 
 
(D) The cells depicted after two passages were live stained for SSEA-4 (using a 
mouse anti-human monoclonal antibody conjugated to NL493). Cells were 
imaged using epifluorescence microscopy under blue light. Scale bar = 500 µm. 
 
(E) Examination of growth kinetics across the 12 different conditions tested over two 
passages (6 conditions under normoxia and 6 conditions under hypoxia). Total 
live cells as measured by trypan blue exclusion was determined and plotted on a 
log10 scale. 
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Figure 11 
 
Figure 11: Direct conversion of alternative rhesus macaque embryonic stem cell 
lines derived from SCNT (CRES-2) or parthenogenesis (rPESC) 
 
(A) Primed pluripotent cells were converted in the indicated conditions (LIF 3i or LIF 
4i) under hypoxia only. Percentage recovery of live cells as measured by trypan 
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(B) Comparative examination of dome shaped morphology across the different in 
vitro culture conditions indicated in (A) after one passage. Cells were imaged 
under phase contrast. Scale bar = 500 µm. 
 
(C) Examination of morphology after two passages in the indicated conditions. Phase 
contrast; scale bar = 500 µm. 
 
(D) The cells depicted after two passages were live stained for SSEA-4 (using a 
mouse anti-human monoclonal antibody conjugated to NL493). Cells were 
imaged using epifluorescence microscopy under blue light. Scale bar = 500 µm. 
 
(E) Examination of growth kinetics across the 2 different conditions tested over two 
passages. Total live cells as measured by trypan blue exclusion was determined 

































Figure 5: LIF 3i converted human pluripotent stem cells display significant 
enrichment in HR pathway genes 
Gene set enrichment analysis for (A) homologous recombination (HR) and (B) non-
homologous end joining (NHEJ) pathways of double-strand break DNA repair. NES 
= normalized enrichment score, ns = not significant. Note: each column on the 
heatmaps represents a different gene. All converted naïve cell lines are shaded in 
grey, while their primed source counterparts are shaded in yellow. Red shades on the 
heatmaps depict upregulation, while blue shades depict downregulation. More 
significant upregulation/downregulation is indicated by darker tones of blue or red. 
Notably, stromal primed cord blood iPSC display more pronounced upregulation of 
HR pathway genes compared to fibroblast iPSC. Note: I am grateful here for the 



























Figure 12: LIF 3i converted human pluripotent stem cells display significant 
enrichment i  HR pathway genes  
 
Gene set enrichment analysis for (A) homologous recombination (HR) and (B) non- 
homologous end joining (NHEJ) pathways of double-strand break DNA rep ir. NES 
= normalized enrichment score, ns = not significant. Each column on the heatmaps 
represents a different gene (indicated below each heatmap). The correseponding 
enrichment plots are depicted to the right of each heatmap, with naïve lines in red (at 
the left of the plot) and primed lines in blue (at the right of the plot). All converted 
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naïve cell lines are shaded in grey, while their primed source counterparts are shaded 
in yellow. Red shades on the heatmaps depict upregulation, while blue shades depict 
downregulation. More significant upregulation/downregulation is indicated by darker 



































































Figure 13: DNA methylation profile across the human OCT4 proximal and distal 
enhancer elements for high performing and low performing lines 
 
Analysis of human Infinium 450k DNA methylation arrays from ground state LIF 3i 
and bFGF source pluripotent stem cells was conducted to investigate a possible 
proximal to distal enhancer regulatory switch upon LIF 3i naïve reversion. The 450k 
array has six probes examining six CpG sites within the OCT4 proximal enhancer, 
and three probes examining three CpG sites within the distal enhancer. Mean 
methylation beta values are indicated for high performing LIF 3i and source bFGF 
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lines (H9 hESC, stromal primed cord blood hiPSC) and low performing LIF 3i and 
bFGF source lines (fibroblast hiPSC). 𝛽 = 1 indicates a fully methylated CpG probe, 



































Figure 14: Possible mechanisms surrounding VEGF receptor inhibition in 
rhesus mESC-like self-renewal 
 
LIF signaling through LIF receptor (LIFR) and gp130 activates STAT3 and classical 
mESC-like self-renewal. LIFR/gp130 activation may also have a secondary effect of 
inhibiting HIF1𝛼/endoplasmic reticulum (ER) stress. In vitro hypoxic culture and 
environmental stress (possibly including single cell dissociation) may act to increase 
VEGF ligand secretion and autocrine VEGF signaling via a HIF1𝛼 /ER stress 
signaling axis. Blocking VEGF receptor (VEGFR) with sunitinib reinforces the 
combined effect of MEK inhibition and GSK3-𝛽  inhibition to prevent rESC 
differentiation. Additionally, blocking VEGFRs with sunitinib may block the feed-
forward loop between VEGFR activation and HIF1𝛼/ER stress, and act to minimize 
tendencies for rESCs to spontaneously differentiate in culture upon autocrine VEGF 
stimulation. Used unmodified from Chen et al. (2014)72. 
	   67	  
REFERENCES 
 
1. Nichols, J. & Smith, A. Naive and primed pluripotent states. Cell Stem Cell 4, 
487–492 (2009). 
2. Mascetti, V. L. & Pedersen, R. A. Naiveté of the human pluripotent stem cell. 
Nat. Biotechnol. 32, 68–70 (2014). 
3. Ying, Q.-L. et al. The ground state of embryonic stem cell self-renewal. Nature 
453, 519–523 (2008). 
4. Hanna, J. H., Saha, K. & Jaenisch, R. Pluripotency and cellular 
reprogramming: facts, hypotheses, unresolved issues. Cell 143, 508–525 
(2010). 
5. Brons, I. G. M. et al. Derivation of pluripotent epiblast stem cells from 
mammalian embryos. Nature 448, 191–195 (2007). 
6. Marks, H. et al. The transcriptional and epigenomic foundations of ground 
state pluripotency. Cell 149, 590–604 (2012). 
7. Tesar, P. J. et al. New cell lines from mouse epiblast share defining features 
with human embryonic stem cells. Nature 448, 196–199 (2007). 
8. Chia, N.-Y. et al. A genome-wide RNAi screen reveals determinants of human 
embryonic stem cell identity. Nature 468, 316–320 (2010). 
9. Hanna, J. et al. Human embryonic stem cells with biological and epigenetic 
characteristics similar to those of mouse ESCs. Proc. Natl. Acad. Sci. U. S. A. 
107, 9222–9227 (2010). 
10. Hedges, S. B., Dudley, J. & Kumar, S. TimeTree: a public knowledge-base of 
divergence times among organisms. Bioinforma. Oxf. Engl. 22, 2971–2972 
(2006). 
	   68	  
11. Nichols, J., Chambers, I., Taga, T. & Smith, A. Physiological rationale for 
responsiveness of mouse embryonic stem cells to gp130 cytokines. Dev. Camb. 
Engl. 128, 2333–2339 (2001). 
12. Kalkan, T. & Smith, A. Mapping the route from naive pluripotency to lineage 
specification. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 369, (2014). 
13. Hanna, J. et al. Metastable pluripotent states in NOD-mouse-derived ESCs. 
Cell Stem Cell 4, 513–524 (2009). 
14. Guo, G. et al. Klf4 reverts developmentally programmed restriction of ground 
state pluripotency. Dev. Camb. Engl. 136, 1063–1069 (2009). 
15. Silva, J. et al. Nanog is the gateway to the pluripotent ground state. Cell 138, 
722–737 (2009). 
16. Zaharevitz, D. W. et al. Discovery and initial characterization of the paullones, 
a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer 
Res. 59, 2566–2569 (1999). 
17. Schultz, C. et al. Paullones, a series of cyclin-dependent kinase inhibitors: 
synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor 
activity. J. Med. Chem. 42, 2909–2919 (1999). 
18. Leost, M. et al. Paullones are potent inhibitors of glycogen synthase kinase-
3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. FEBS 267, 5983–
5994 (2000). 
19. Lyssiotis, C. A. et al. Reprogramming of murine fibroblasts to induced 
pluripotent stem cells with chemical complementation of Klf4. Proc. Natl. 
Acad. Sci. U. S. A. 106, 8912–8917 (2009). 
	   69	  
20. Wang, W. et al. Rapid and efficient reprogramming of somatic cells to induced 
pluripotent stem cells by retinoic acid receptor gamma and liver receptor 
homolog 1. Proc. Natl. Acad. Sci. U. S. A. 108, 18283–18288 (2011). 
21. Gafni, O. et al. Derivation of novel human ground state naive pluripotent stem 
cells. Nature 504, 282–286 (2013). 
22. Chan, Y.-S. et al. Induction of a human pluripotent state with distinct 
regulatory circuitry that resembles preimplantation epiblast. Cell Stem Cell 13, 
663–675 (2013). 
23. Valamehr, B. et al. Platform for induction and maintenance of transgene-free 
hiPSCs resembling ground state pluripotent stem cells. Stem Cell Rep. 2, 366–
381 (2014). 
24. Ware, C. B. et al. Derivation of naive human embryonic stem cells. Proc. Natl. 
Acad. Sci. U. S. A. 111, 4484–4489 (2014). 
25. Theunissen, T. W. et al. Systematic identification of culture conditions for 
induction and maintenance of naive human pluripotency. Cell Stem Cell 15, 
471–487 (2014). 
26. Takashima, Y. et al. Resetting transcription factor control circuitry toward 
ground-state pluripotency in human. Cell 158, 1254–1269 (2014). 
27. Fang, R. et al. Generation of naive induced pluripotent stem cells from rhesus 
monkey fibroblasts. Cell Stem Cell 15, 488–496 (2014). 
28. Van Oosten, A. L., Costa, Y., Smith, A. & Silva, J. C. R. JAK/STAT3 
signalling is sufficient and dominant over antagonistic cues for the 
establishment of naive pluripotency. Nat. Commun. 3, 817 (2012). 
	   70	  
29. Dutta, D. et al. Self-renewal versus lineage commitment of embryonic stem 
cells: protein kinase C signaling shifts the balance. Stem Cells Dayt. Ohio 29, 
618–628 (2011). 
30. Hanna – Protocols. at <http://hannalabweb.weizmann.ac.il/?page_id=129> 
31. Ying, Q.-L., Stavridis, M., Griffiths, D., Li, M. & Smith, A. Conversion of 
embryonic stem cells into neuroectodermal precursors in adherent 
monoculture. Nat. Biotechnol. 21, 183–186 (2003). 
32. Ying, Q. L., Nichols, J., Chambers, I. & Smith, A. BMP induction of Id 
proteins suppresses differentiation and sustains embryonic stem cell self-
renewal in collaboration with STAT3. Cell 115, 281–292 (2003). 
33. Wiles, M. V. & Johansson, B. M. Embryonic stem cell development in a 
chemically defined medium. Exp. Cell Res. 247, 241–248 (1999). 
34. Malaguti, M. et al. Bone morphogenic protein signalling suppresses 
differentiation of pluripotent cells by maintaining expression of E-Cadherin. 
eLife 2, e01197 (2013). 
35. Zhang, K. et al. Distinct functions of BMP4 during different stages of mouse 
ES cell neural commitment. Dev. Camb. Engl. 137, 2095–2105 (2010). 
36. Davies, O. R. et al. Tcf15 primes pluripotent cells for differentiation. Cell Rep. 
3, 472–484 (2013). 
37. Huang, S.-M. A. et al. Tankyrase inhibition stabilizes axin and antagonizes 
Wnt signalling. Nature 461, 614–620 (2009). 
38. Kim, H. et al. Modulation of β-catenin function maintains mouse epiblast stem 
cell and human embryonic stem cell self-renewal. Nat. Commun. 4, 2403 
(2013). 
	   71	  
39. Chen, B. et al. Small molecule-mediated disruption of Wnt-dependent 
signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5, 100–107 
(2009). 
40. Faunes, F. et al. A membrane-associated β-catenin/Oct4 complex correlates 
with ground-state pluripotency in mouse embryonic stem cells. Dev. Camb. 
Engl. 140, 1171–1183 (2013). 
41. Marucci, L. et al. β-catenin fluctuates in mouse ESCs and is essential for 
Nanog-mediated reprogramming of somatic cells to pluripotency. Cell Rep. 8, 
1686–1696 (2014). 
42. Zwaka, T. P. & Thomson, J. A. Homologous recombination in human 
embryonic stem cells. Nat. Biotechnol. 21, 319–321 (2003). 
43. Irion, S. et al. Identification and targeting of the ROSA26 locus in human 
embryonic stem cells. Nat. Biotechnol. 25, 1477–1482 (2007). 
44. Davis, R. P. et al. Targeting a GFP reporter gene to the MIXL1 locus of human 
embryonic stem cells identifies human primitive streak-like cells and enables 
isolation of primitive hematopoietic precursors. Blood 111, 1876–1884 (2008). 
45. Ruby, K. M. & Zheng, B. Gene targeting in a HUES line of human embryonic 
stem cells via electroporation. Stem Cells Dayt. Ohio 27, 1496–1506 (2009). 
46. Xue, H. et al. A targeted neuroglial reporter line generated by homologous 
recombination in human embryonic stem cells. Stem Cells Dayt. Ohio 27, 
1836–1846 (2009). 
47. Ishii, A., Kurosawa, A., Saito, S. & Adachi, N. Analysis of the role of 
homology arms in gene-targeting vectors in human cells. PloS One 9, e108236 
(2014). 
	   72	  
48. Alba, R., Bosch, A. & Chillon, M. Gutless adenovirus: last-generation 
adenovirus for gene therapy. Gene Ther. 12 Suppl 1, S18–27 (2005). 
49. Li, M., Suzuki, K., Kim, N. Y., Liu, G.-H. & Izpisua Belmonte, J. C. A cut 
above the rest: targeted genome editing technologies in human pluripotent stem 
cells. J. Biol. Chem. 289, 4594–4599 (2014). 
50. Smith, S., Giriat, I., Schmitt, A. & de Lange, T. Tankyrase, a poly(ADP-ribose) 
polymerase at human telomeres. Science 282, 1484–1487 (1998). 
51. Cook, B. D., Dynek, J. N., Chang, W., Shostak, G. & Smith, S. Role for the 
related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. 
Mol. Cell. Biol. 22, 332–342 (2002). 
52. Bristow, R. G. & Hill, R. P. Hypoxia and metabolism. Hypoxia, DNA repair 
and genetic instability. Nat. Rev. Cancer 8, 180–192 (2008). 
53. Weterings, E. & Chen, D. J. The endless tale of non-homologous end-joining. 
Cell Res. 18, 114–124 (2008). 
54. Dregalla, R. C. et al. Regulatory roles of tankyrase 1 at telomeres and in DNA 
repair: suppression of T-SCE and stabilization of DNA-PKcs. Aging 2, 691–
708 (2010). 
55. Paulk, N. K., Loza, L. M., Finegold, M. J. & Grompe, M. AAV-mediated gene 
targeting is significantly enhanced by transient inhibition of nonhomologous 
end joining or the proteasome in vivo. Hum. Gene Ther. 23, 658–665 (2012). 
56. Durant, S. & Karran, P. Vanillins--a novel family of DNA-PK inhibitors. 
Nucleic Acids Res. 31, 5501–5512 (2003). 
57. Ohta, T. Modification of genotoxicity by naturally occurring flavorings and 
their derivatives. Crit. Rev. Toxicol. 23, 127–146 (1993). 
	   73	  
58. Watanabe, K., Ohta, T., Watanabe, M., Kato, T. & Shirasu, Y. Inhibition of 
induction of adaptive response by o-vanillin in Escherichia coli B. Mutat. Res. 
243, 273–280 (1990). 
59. Keshava, C., Keshava, N., Ong, T. M. & Nath, J. Protective effect of vanillin 
on radiation-induced micronuclei and chromosomal aberrations in V79 cells. 
Mutat. Res. 397, 149–159 (1998). 
60. Gustafson, D. L. et al. Vanillin (3-methoxy-4-hydroxybenzaldehyde) inhibits 
mutation induced by hydrogen peroxide, N-methyl-N-nitrosoguanidine and 
mitomycin C but not (137)Cs gamma-radiation at the CD59 locus in human-
hamster hybrid A(L) cells. Mutagenesis 15, 207–213 (2000). 
61. Maurya, D. K., Adhikari, S., Nair, C. K. K. & Devasagayam, T. P. A. DNA 
protective properties of vanillin against gamma-radiation under different 
conditions: possible mechanisms. Mutat. Res. 634, 69–80 (2007). 
62. Rashid, T., Kobayashi, T. & Nakauchi, H. Revisiting the flight of Icarus: 
making human organs from PSCs with large animal chimeras. Cell Stem Cell 
15, 406–409 (2014). 
63. Tachibana, M. et al. Generation of chimeric rhesus monkeys. Cell 148, 285–
295 (2012). 
64. Kobayashi, T. et al. Generation of rat pancreas in mouse by interspecific 
blastocyst injection of pluripotent stem cells. Cell 142, 787–799 (2010). 
65. Usui, J. et al. Generation of kidney from pluripotent stem cells via blastocyst 
complementation. Am. J. Pathol. 180, 2417–2426 (2012). 
66. Isotani, A., Hatayama, H., Kaseda, K., Ikawa, M. & Okabe, M. Formation of a 
thymus from rat ES cells in xenogeneic nude mouse↔rat ES chimeras. Genes 
Cells Devoted Mol. Cell. Mech. 16, 397–405 (2011). 
	   74	  
67. Matsunari, H. et al. Blastocyst complementation generates exogenic pancreas 
in vivo in apancreatic cloned pigs. Proc. Natl. Acad. Sci. U. S. A. 110, 4557–
4562 (2013). 
68. Kobayashi, T., Kato-Itoh, M. & Nakauchi, H. Targeted organ generation using 
Mixl1-inducible mouse pluripotent stem cells in blastocyst complementation. 
Stem Cells Dev. 24, 182–189 (2015). 
69. Mitalipov, S. et al. Isolation and characterization of novel rhesus monkey 
embryonic stem cell lines. Stem Cells Dayt. Ohio 24, 2177–2186 (2006). 
70. Byrne, J. A. et al. Producing primate embryonic stem cells by somatic cell 
nuclear transfer. Nature 450, 497–502 (2007). 
71. Dighe, V. et al. Heterozygous embryonic stem cell lines derived from 
nonhuman primate parthenotes. Stem Cells Dayt. Ohio 26, 756–766 (2008). 
72. Chen, G. et al. Blocking autocrine VEGF signaling by sunitinib, an anti-cancer 
drug, promotes embryonic stem cell self-renewal and somatic cell 
reprogramming. Cell Res. 24, 1121–1136 (2014). 
73. Forristal, C. E., Wright, K. L., Hanley, N. A., Oreffo, R. O. C. & Houghton, F. 
D. Hypoxia inducible factors regulate pluripotency and proliferation in human 
embryonic stem cells cultured at reduced oxygen tensions. Reprod. Camb. 
Engl. 139, 85–97 (2010). 
74. Wang, Q. et al. Lithium, an anti-psychotic drug, greatly enhances the 
generation of induced pluripotent stem cells. Cell Res. 21, 1424–1435 (2011). 
75. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based 
approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. 
Sci. U. S. A. 102, 15545–15550 (2005). 
	   75	  
76. Allegrucci, C. et al. Human embryonic stem cells as a model for nutritional 
programming: an evaluation. Reprod. Toxicol. Elmsford N 20, 353–367 (2005). 
77. Skottman, H. et al. Gene expression signatures of seven individual human 
embryonic stem cell lines. Stem Cells Dayt. Ohio 23, 1343–1356 (2005). 
78. International Stem Cell Initiative et al. Characterization of human embryonic 
stem cell lines by the International Stem Cell Initiative. Nat. Biotechnol. 25, 
803–816 (2007). 
79. Allegrucci, C. & Young, L. E. Differences between human embryonic stem 
cell lines. Hum. Reprod. Update 13, 103–120 (2007). 
80. Osafune, K. et al. Marked differences in differentiation propensity among 
human embryonic stem cell lines. Nat. Biotechnol. 26, 313–315 (2008). 
81. Choi, K.-D. et al. Hematopoietic and endothelial differentiation of human 
induced pluripotent stem cells. Stem Cells Dayt. Ohio 27, 559–567 (2009). 
82. Hu, B.-Y. et al. Neural differentiation of human induced pluripotent stem cells 
follows developmental principles but with variable potency. Proc. Natl. Acad. 
Sci. U. S. A. 107, 4335–4340 (2010). 
83. Feng, Q. et al. Hemangioblastic derivatives from human induced pluripotent 
stem cells exhibit limited expansion and early senescence. Stem Cells Dayt. 
Ohio 28, 704–712 (2010). 
84. Boulting, G. L. et al. A functionally characterized test set of human induced 
pluripotent stem cells. Nat. Biotechnol. 29, 279–286 (2011). 
85. Waddington, C. H. The Strategy of the Genes. A Discussion of Some Aspects 
of Theoretical Biology. With an appendix by H. Kacser. ix +–262 pp. (1957). 
86. Goldberg, A. D., Allis, C. D. & Bernstein, E. Epigenetics: a landscape takes 
shape. Cell 128, 635–638 (2007). 
	   76	  
87. Zhang, J. et al. BMP induces cochlin expression to facilitate self-renewal and 
suppress neural differentiation of mouse embryonic stem cells. J. Biol. Chem. 
288, 8053–8060 (2013). 
88. Onishi, K., Tonge, P. D., Nagy, A. & Zandstra, P. W. Local BMP-SMAD1 
signaling increases LIF receptor-dependent STAT3 responsiveness and 
primed-to-naive mouse pluripotent stem cell conversion frequency. Stem Cell 
Rep. 3, 156–168 (2014). 
89. Tonge, P. D. et al. Divergent reprogramming routes lead to alternative stem-
cell states. Nature 516, 192–197 (2014). 
90. Shimizu, T. et al. Dual inhibition of Src and GSK3 maintains mouse 
embryonic stem cells, whose differentiation is mechanically regulated by Src 
signaling. Stem Cells Dayt. Ohio 30, 1394–1404 (2012). 
91. Wolf, D. P. et al. Use of assisted reproductive technologies in the propagation 
of rhesus macaque offspring. Biol. Reprod. 71, 486–493 (2004). 
92. Ezashi, T., Das, P. & Roberts, R. M. Low O2 tensions and the prevention of 
differentiation of hES cells. Proc. Natl. Acad. Sci. U. S. A. 102, 4783–4788 
(2005). 
93. Han, Y., Kuang, S.-Z., Gomer, A. & Ramirez-Bergeron, D. L. Hypoxia 
influences the vascular expansion and differentiation of embryonic stem cell 
cultures through the temporal expression of vascular endothelial growth factor 
receptors in an ARNT-dependent manner. Stem Cells Dayt. Ohio 28, 799–809 
(2010). 
94. Lee, S.-W. et al. Hypoxic priming of mESCs accelerates vascular-lineage 
differentiation through HIF1-mediated inverse regulation of Oct4 and VEGF. 
EMBO Mol. Med. 4, 924–938 (2012). 
	   77	  
95. Mazumdar, J. et al. O2 regulates stem cells through Wnt/β-catenin signalling. 
Nat. Cell Biol. 12, 1007–1013 (2010). 
96. Kubota, Y., Hirashima, M., Kishi, K., Stewart, C. L. & Suda, T. Leukemia 
inhibitory factor regulates microvessel density by modulating oxygen-
dependent VEGF expression in mice. J. Clin. Invest. 118, 2393–2403 (2008). 
97. Conley, S. J. et al. Antiangiogenic agents increase breast cancer stem cells via 
the generation of tumor hypoxia. Proc. Natl. Acad. Sci. U. S. A. 109, 2784–
2789 (2012). 
98. Yusa, K. et al. Targeted gene correction of α1-antitrypsin deficiency in induced 
pluripotent stem cells. Nature 478, 391–394 (2011). 
99. Zou, J., Mali, P., Huang, X., Dowey, S. N. & Cheng, L. Site-specific gene 
correction of a point mutation in human iPS cells derived from an adult patient 
with sickle cell disease. Blood 118, 4599–4608 (2011). 
100. Yusa, K. Seamless genome editing in human pluripotent stem cells using 
custom endonuclease-based gene targeting and the piggyBac transposon. Nat. 
Protoc. 8, 2061–2078 (2013). 
101. Sun, N. & Zhao, H. Seamless correction of the sickle cell disease mutation of 
the HBB gene in human induced pluripotent stem cells using TALENs. 
Biotechnol. Bioeng. 111, 1048–1053 (2014). 
102. Xie, F. et al. Seamless gene correction of β-thalassemia mutations in patient-
specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res. 24, 1526–
1533 (2014). 
103. Dunn, S.-J., Martello, G., Yordanov, B., Emmott, S. & Smith, A. G. Defining 
an essential transcription factor program for naïve pluripotency. Science 344, 
1156–1160 (2014). 
	   78	  
104. Huang, K., Maruyama, T. & Fan, G. The naive state of human pluripotent stem 
cells: a synthesis of stem cell and preimplantation embryo transcriptome 
analyses. Cell Stem Cell 15, 410–415 (2014). 
105. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 
(2006). 
106. Barth, T. K. & Imhof, A. Fast signals and slow marks: the dynamics of histone 
modifications. Trends Biochem. Sci. 35, 618–626 (2010). 
107. Martello, G. & Smith, A. The Nature of Embryonic Stem Cells. Annu. Rev. 
Cell Dev. Biol. 30, 647–675 (2014). 
108. Robinton, D. A. & Daley, G. Q. The promise of induced pluripotent stem cells 
in research and therapy. Nature 481, 295–305 (2012). 
109. Park, T. S. et al. Growth factor-activated stem cell circuits and stromal signals 
cooperatively accelerate non-integrated iPSC reprogramming of human 
myeloid progenitors. PloS One 7, e42838 (2012). 
110. The 2007 Nobel Prize in Physiology or Medicine - Advanced Information. at 
<http://www.nobelprize.org/nobel_prizes/medicine/laureates/2007/advanced.ht
ml> 
111. Kim, H. & Kim, J.-S. A guide to genome engineering with programmable 











Sarshan Rubintheran Pather 
 
Date of Birth:   14th November 1994 (Age 20) 
 
Birthplace:   Durban, South Africa 
 
Nationality:   South African 
 







2014 - 2015:   M.S. Molecular and Cellular Biology (GPA: 4.00) 
The Zambidis Laboratory 
Johns Hopkins University 
 
2012 - 2013:   Hopkins-St. Anne’s Pre-Medical Honors Program 
Molecular and Cellular Biochemistry 
University of Oxford 
 
2011 - 2014:   B.S. Molecular and Cellular Biology (with Honors; GPA: 3.97) 
Johns Hopkins University 
 






2013 - 2015:  Research Assistant in Stem Cell Biology  
The Zambidis Laboratory 
Johns Hopkins University School of Medicine 
 
2014 - 2015: Teaching Assistant, General Biology (Lecture and Laboratory) 
   Johns Hopkins University 
 
2013:  Oncology Shadowing (with Dr. Elias T. Zambidis, MD/PhD) 
 Johns Hopkins University School of Medicine 
   
2012:   Accident and Emergency Trauma Unit Medical Orderly 
Chatsmed Garden Hospital, Durban, South Africa 
 
2011:    General Surgery Shadowing  
Chatsmed Garden Hospital, Durban, South Africa 
	   80	  
Volunteer Service and Leadership 
(During B.S. and M.S. Degrees) 
 
President of JHU GED Tutoring 
President of JHU Golden Key International Honor Society 







Beta Beta Beta (Tri-Beta) National Biological Honor Society 
Presented B.S. Honors Thesis at the Tri-Beta Poster Session (2014) 
Phi Beta Kappa  
Golden Key International Honor Society 
Oxford University Scientific Society 
 
 
Music and Athletic Achievement 
 
Grade 5 Piano Certificate 
Associated Board of the Royal Schools of Music 
Grade 5 Alto Saxophone Certificate 
Associated Board of the Royal Schools of Music 
 
JHU Jazz Band 
JHU Golf Club 
Oxford University and St. Anne’s College 1st/2nd XI Cricket Team 
 
 
 
 
 
